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Abstract 
Pregnancy alters substrate metabolism by altering 
cytochrome P450 (CYP) enzymes. This superfamily is classified 
by amino acid sequence identity. CYP3Al is the first member 
of family 3, subfamily A. 
An HPLC method was used to identify a specific protein, 
cytochrome P450gest, that is induced in maternal liver during 
gestation in the C57Bl/6J mouse but is not induced by known 
exogenous CYP inducers. This study examines the regulation of 
P450gest in mice in different hormonal states and reports its 
purification, metabolic function and N-terminal sequence. 
Hepatic microsomal P450gest content decreased after 
parturition in both lactating and nonlactating mothers then 
increased to the pregnant mouse level in lactating mothers. 
In virgin females, prolactin treatment for seventeen days had 
a small inducing effect on P450gest. Growth hormone plus 
hydrocortisone induced P450gest to the pregnant level. 
Estradiol, progesterone or both added to the growth hormone, 
hydrocortisone treatment had no further effect on P450gest. 
Prolactin added to growth hormone and hydrocortisone decreased 
P450gest to the virgin female level. 
P450gest was purified from pregnant mouse hepatic 
iii 
microsomes using the HPLC profile to monitor the protein. The 
protein separated as a single HPLC peak following open column 
AH-Sepharose and HPLC DEAE-5PW chromatography. A 
hydroxylapatite HPLC column separated the protein into two 
peaks named P450gest 1 and gest2 in the order of elution. 
Their N-terminal amino acid sequence differed only at the 
second residue. Both proteins had 74% and 48% identity with 
male mouse CYP3All and 3A13, respectively and less that 25% 
identity with other mouse CYP proteins, suggesting that 
P450gest is part of the CYP3A family. When purified P450gest 
was reconstituted with lipid and cytochrome b5 it metabolized 
testosterone in the 6~ and the 2~ positions, a characteristic 
of the CYP3A subfamily. 
Screening a pregnant mouse liver cDNA library yielded two 
cDNA sequences that translated into 146 and 84 amino acid 
peptides. These proteins had 87% amino acid identity with 
each other and 90% and 68% identity with the carboxyl terminal 
of CYP3All and CYP3A13, respectively. This suggests the 
presence of four mouse CYP3A proteins the same as in humans 
and rats. 
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:Introduction 
Pregnancy alters the rate of metabolism of several drugs 
in humans and in laboratory animals. In mice the changes in 
drug metabolism have been associated with changes in specific 
cytochromes P450 (Lambert et al. 1987). 
The cytochrome P450 (P450) dependent mixed function 
monooxygenase system metabolizes many substances including 
endogenous substrates such as steroids, and xenobiotic or 
foreign substrates such as chemicals and drugs. The enzymes 
metabolize nonpolar molecules into hydrophilic compounds that 
can be excreted more readily than the parent compound. The 
level of P450 in the liver can be changed by exposure to 
xenobiotic agents including drugs such as phenobarbital or 
certain chemicals (Okey 1990). When a xenobiotic changes the 
level of a specific P450, the level of metabolites or the type 
of metabolites produced can change thereby altering toxicity 
or the physiological effect of the parent compound (Gonzalez 
et al. 1987, Nebert et al. 1987). 
Specific cytochrome P450s have a role in xenobiotic 
induced cancer, mutations and birth defects (Nebert and 
Bigelow 1982, Guengerich 1990) because they metabolize their 
substrates to compounds that are capable of binding to protein 
or DNA, one step leading to carcinogenesis or mutagenesis 
Guengerich 1988, Wolff and Trecker 1992). Maternal and fetal 
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genetic differences in the capacity for induction of these 
p4sos can alter toxicity by altering the amount of metabolites 
produced that can covalently bind to fetal tissues (Lambert 
and Nebert 1977). Some P450s are active in synthesizing or 
metabolizing endogenous substrates such as steroids or 
prostaglandins that play an important role in cellular growth 
or pregnancy. 
We have identified cytochrome P450gest by changes in the 
HPLC elution profile of hepatic microsomes and have shown that 
it is induced in mouse liver during pregnancy. The rapid 
increase in P450gest early in pregnancy suggested that 
P450gest is regulated by endogenous factors including either 
steroid of peptide hormones. This study tested that 
hypothesis by examining the regulation of cytochrome P450gest 
in mice in different hormonal states including lactation and 
treatment with individual or combinations of hormones. The 
protein was purified from hepatic microsomes of pregnant mice 
and the N-terminal amino acid sequence was used to tentatively 
classify it as a member of the P450 family 3A. The protein 
was used to develop polyclonal antibodies that were used to 
isolate clones from an expression cDNA library prepared from 
pregnant mice. This was part of a long term goal to determine 
the regulatory mechanism of P450gest that permits the rapid 
changes in the level of P450gest that occur in mouse liver 
during pregnancy and during lactation. 
Literature Review 
pregnancy and Drug Metabolism 
Pregnancy can increase or decrease the elimination of 
drugs in humans and in laboratory animals. Caffeine 
elimination is decreased during human pregnancy but returns to 
the nonpregnant level within one week to one month of delivery 
(Knutti et al. 1981, Ortweiler et al. 1985) . Metamizol 
elimination also decreases during pregnancy but does not 
return to nonpregnant level as rapidly as caffeine elimination 
(Ortweiler et al. 1985) . Other drugs including metoprolol and 
phenytoin are eliminated more rapidly by pregnant as compared 
to postpartum women {Hogstedt et al. 1985). 
These observations in humans parallel results from 
experiments in laboratory animals. Some substrates are 
metabolized more rapidly during pregnancy while other 
substrates have reduced rates of metabolism. The specificity 
of the direction of change for different substrates suggests 
that this is not a general change in some physiological 
function but rather a specific change in the metabolic 
pathway. This concept is supported by in vitro studies of 
metabolism using hepatic microsomes prepared from pregnant and 
nonpregnant animals. In mice, aminopyrine N-demethylation per 
nanomole of P450 content decreases during gestation, while 
3 
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ethyl morphine N-demethylation is relatively constant (Lambert 
et al. 1987). In rats, pregnancy decreases the micros·omal 
oxidation of benzyl alcohol by two or three specific P450s, 
P450 2El and P450 2Cll/6 (Nakajima et al. 1992). In pregnant 
hamsters hepatic mRNA levels for P450 2E are decreased with 
only small changes in the protein levels as measured by 
immunoblots. Pregnancy also blocks ethanol induction of 
P4502E mRNA and protein (Miller et al. 1992, Jorquera et al. 
1992) . Pregnancy-induced changes in specific P450 proteins 
are reflected in differences in metabolism of N-nitrosamino 4 
(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a substance in 
tobacco that can be activated to a potent carcinogen by 
oxidation of the a-carbon. 
Definition and Nomenclature for cytochrome P450 
Metabolism of drugs and chemicals proceeds in two phases. 
Phase I metabolism introduces a hydrophilic site such as a 
hydroxide or epoxide group into a hydrophobic molecule. Phase 
II metabolism increases the hydrophilic nature of the 
substrate by adding an endogenous molecule such as glucuronic 
acid or glutathione to the functional group produced by phase 
I reactions (Benet and Sheiner 1985, Nebert 1991) • The 
cytochrome P450s are phase I enzymes. 
The cytochrome P450 dependent mixed function 
monooxygenases are a superfamily of membrane bound enzymes 
that contain a noncovalently bound heme, and use reducing 
equivalents from NADPH or NADH and one atom from a molecule of 
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oxygen to oxygenate substrates (Nebert and Gonzalez 1987). 
The enzymes are active in the metabolism of endogenous 
substrates including steroid hormones, vitamin D, retinoic 
acid, prostaglandins, leukotrienes and fatty acids. In 
addition exogenous substrates including aromatic hydrocarbons, 
polyhalogenated biphenyls, drugs such as caffeine and 
phenobarbital, macrolide antibiotics such as erythromycin and 
rifampicin, and small volatile organic molecules including 
ethanol, acetone and toluene are metabolized by one or more 
enzymes in the superfamily (Guengerich 1990). The types of 
reactions which are catalyzed include demethylation at a 
nitrogen, oxygen or sulfur atom, hydroxylation at a carbon-
hydrogen bond and epoxidation (Porter and Coon 1991). The 
common mechanism in these reactions is insertion of one atom 
of an oxygen molecule into the substrate. This insertion may 
be followed by a dealkylation step. The active site in the 
enzyme contains a noncovalently bound heme moiety. In higher 
organisms, the enzyme is membrane bound either in the 
endoplasmic reticulum or in mitochondria and metabolic 
activity is lost when the protein is purified and removed from 
the lipid environment. The cytochrome P450 is inserted into 
the membrane by the amino terminal segment of at least thirty 
amino acids (Sakaguchi et al. 1987). This segment contains a 
leucine rich segment of uncharged amino acids that is highly 
conserved in microsomal cytochrome P450s. The cytochrome P450 
protein is closely associated with an NADPH or NADH dependent 
6 
cytochrome P-450 reductase within the lipid layer. Cytochrome 
b is also needed for maximal catalytic activity for some of 
5 
the cytochrome P450s (Jansson et al. 1985). The oxidation 
reaction begins when the endogenous or xenobiotic substrate 
binds to the cytochrome P-450 reductase complex. The heme 
iron is reduced using one electron donated by the NADPH 
dependent P450 reductase, molecular oxygen binds to the 
reduced enzyme complex and another electron is donated to the 
enzyme complex either by the NADPH dependent P450 reductase or 
by cytochrome b5 • One of the oxygen atoms is protonated to 
produce one water molecule and the second oxygen atom is 
incorporated into the substrate by insertion between two 
atoms. Insertion between a carbon and a hydrogen produces a 
hydroxy lated substrate. When the oxygen insertion occurs 
between one carbon and a hydrogen of an alkyl side chain on a 
structural carbon, nitrogen or oxygen the insertion is 
followed by loss of the side chain as an aldehyde (Guengerich 
1990) . 
The amount of a specific P450 in a tissue can be induced 
by hormonal changes during development or by exposure to 
specific drugs or other chemicals. Early investigations of 
P450 used induction of a specific activity by treatment with 
arylhydrocarbons, especially 
phenobarbital and purification 
3-methylcholanthrene 
by chromatography 
or 
and 
electrophoreses to isolate a protein with known metabolic 
activity. Individual P450s were named on the basis of the 
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inducing agent or the purification properties. This led to a 
confusing system with a single P450 having several names 
because it was not possible to determine whether two proteins 
isolated in different laboratories by different protocols were 
actually the same enzyme. When amino acid sequences, 
frequently deduced from cDNA sequences, became available, a 
nomenclature system based on similarity of amino acid 
sequences replaced this early practice (Nebert et al. 1987, 
1989). In this system, each enzyme in the superfamily has a 
family name beginning with the letters CYP, for cytochrome 
P450, followed by a numeral designating the family. For most 
species the protein and the gene have the same name. The 
names for genes for mouse P450s use the conventional system 
for mouse genes with lower case italic letters. For example 
the mouse protein CYPlAl is encoded by the gene Cypla-1. 
(Nebert et al. 1989). 
Cytochromes P450 with amino acid sequence homology less 
than 36% are placed in different families. The most recent 
tabulation of cytochrome P450 genes lists twelve mammalian 
families (Nelson et al. 1993). Some families are given 
numerical names, CYPl, CYP2, CYP3 or CYP4, based on the order 
of discovery. cytochrome P450 families involved in steroid 
synthesis have numerical names associated with the metabolic 
activity. For example, the enzyme family active in converting 
androgens to estrogens is CYP19 because of the loss of carbon 
19 when the aromatic carbon is produced. 
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The CYP families are made up of one or more subfamilies. 
proteins with greater the 55% amino acid homology are ih the 
same subfamily. CYP subfamilies are designated by a letter 
following the family number. The number of subfamilies in a 
cYP family varies from one (CYPll, CYP19) to at least eleven 
(CYP2). In CYP subfamilies with several members, it is not 
always possible to determine if proteins with only a few amino 
acid differences isolated from different species are actually 
the same protein. The problem of associating genes with very 
similar sequences isolated from different species is related 
to evolutionary divergence of the species. Orthologous genes 
are defined as genes that occur in two species corresponding 
to the same gene that existed before the two species separated 
during evolution (Nebert et al. 1991). Where there are only 
two members in a subfamily, as in CYPlA, orthologous genes in 
different species can be determined by sequence comparison and 
by similarities in metabolic reactions and inducing agents. 
Subfamily CYPlA contains only two members, CYPlAl and CYP1A2 
and sequences from rat, human, mouse and other species can be 
identified as either a CYPlAl or a 1A2. 
In subfamilies with three or more members, sequence 
homology between proteins or DNA from different species may 
not clearly designate orthologous genes for at least three 
reasons. One factor that makes assignment of orthologous 
genes difficult is that relatively minor changes in amino acid 
sequence can alter substrate binding and metabolism so that a 
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comparison of metabolic reactions is not possible. A second 
factor is that gene duplication or gene conversion in one 
species but not another decrease the differences between the 
genes in one species making orthologous genes difficult to 
identify. One example of gene conversion that decreases the 
differences between genes occurs in CYPJAl and JA2 which have 
an overall amino acid homology of 89%. These two genes have 
one 400 bp DNA sequence that is 100% homologous that is 
probably the result of a gene conversion event (Gonzalez et 
al. 1986). A third factor that cannot be used to determine if 
genes in different species are related to a common ancestral 
gene is gene regulation. For example, phenobarbital can 
induce some CYP proteins in family 2 and some CYP proteins in 
family 3 but other proteins in these families are not induced 
by phenobarbital {Gonzalez 1989). In gene subfamilies with 
more than two members, each member is given a different number 
(Nebert et al. 1991). In the CYPJA subfamily every protein 
has a different subfamily number because there are at least 
four different genes in humans and therefore which genes in 
other species are orthologous to the human genes has not been 
established. There are at least thirteen members from seven 
species in the CYPJA subfamily. 
In the CYP family and subfamily classification scheme 
related genes and proteins are placed into the same group 
according to two characteristics of the DNA. One of these 
characteristics is chromosome location. For example, the rat 
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CYP2D subfamily has four closely linked genes arranged head to 
tail on a 60 kb DNA segment (Matsunaga et al. 1990). Of the 
twenty two known mammalian subfamilies, seventeen human and 
fifteen mouse genes have been mapped to a specific 
subchromosomal locations. In each case the subfamily has a 
single locus (Nelson et al. 1993) . A second characteristic of 
related genes is their exon-intron structure. In those 
examples where genomic structures are known, the members of a 
subfamily have the same exon-intron structure. The four genes 
in the rat CYP2D subfamily all contain nine exons with a high 
degree of nucleotide sequence identity within the exons and 
within some regions of the introns (Matsunaga et al. 1990). 
This conservation of the number of exons can be found in 
members of the same subfamily from different species. The rat 
CYP3A gene and the human fetal CYP3A7 gene are each made up of 
thirteen exons, an unusually large number for CYP genes 
(Miyata et al. 1991, Itoh et al. 1992). The genomic 
structures of other CYP3As are not available for comparison. 
Sequences of proteins from different strains or 
individuals are considered to be allelic variants if the 
proteins have amino acid identity ~97%, however there are 
exceptions in which closely related proteins are known to be 
encoded by different genes. Proteins that are allelic 
variants are the CYP3Als isolated from Sprague Dawley and 
Wistar rats that are 99.5% homologous with only three 
differences in a sequence of 504 amino acids (Riberea and 
11 
r,echner 1992). An example of allelic variance in mice occurs 
between two inbred strains, OBA and C57BL/6, in CYP1A2 where 
there are only three nucleotide differences in the cDNA from 
the two strains and two of these changes are downstream of the 
stop codon (Kimura and Nebert 1986). Examples of proteins with 
amino acid identity >97% known to be encoded by different 
genes and therefore given different names are rat CYP2Bl and 
2B2 or mouse CYP2A4 and 2A5 (Nelson et al. 1993). Another 
pair of P450s with sequence identity greater than 97% that are 
considered to arise from different genes are human P450NF 
(CYP3A3) and P450p (CYP3A4) that were isolated from the same 
human liver library (Beaune et al. 1986, Molowa et al. 1986). 
In contrast, clone phPCNl isolated from a different liver 
library has 98% amino acid sequence identity with P450p but 
they are believed to be encoded by different genes because 
P450p has a nineteen base pair insertion in the untranslated 
3 ' end compared to phPCNl ( Bork et al. 
phPCNl and P450p have different names, 
1989) . Therefore 
CYP3A3 and CYP3A4 
respectively. The sequences for P450NF and phPCNl are in the 
same subfamily (CYP3A3) and are believed to be the same gene 
since they have only one amino acid difference (Gonzalez et 
al. 1988). 
Significance of Amino Acid Substitutions in CYP Proteins 
A change in only one or a very few amino acids in a P450 
can change the substrate specificity, the inducibility or the 
interaction with cytochrome b5 • Genes Cyp2a-4 and Cyp2a-5 
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encode proteins of 494 amino acids with only eleven 
substitutions. However when the proteins are expressed 
individually in C0S-1 cells, the two enzymes have very 
different metabolic profiles. CYP2A4 has lSa-hydroxylase 
activity for testosterone, progesterone, and androstenedione 
while CYP2AS has very little steroid hydroxylase activity but 
has coumarin 7-hydroxylase activity (Lindberg and Negishi 
1989). CYP2AS, but not 2A4, can be induced by pyrazole or 
phenobarbital. 
site directed mutagenesis of each of these eleven amino 
acids in CYP2AS to the amino acid in CYP2A4 and expression in 
COS-1 cells has been used to demonstrate that only three of 
these amino acid changes are necessary to change the enzyme's 
metabolic activity. Changing any one of these three amino 
acids in CYP2AS to the amino acid of CYP2A4 will decrease 
coumarin 7-hydroxylase activity and increase testosterone lSa-
hydroxylase activity. Changing all three will completely 
restore testosterone metabolism and block coumarin hydroxylase 
activity (Lindberg and Negishi 1989). 
Gene Regulation for cytochrome P450 
Very low levels of most of the CYP proteins are detected 
in fetal livers. Activation of these enzymes occurs at 
various ages depending on the species and the specific P450. 
Rat CYP2El is an example of a P450 that increases within a few 
hours after birth. The increase occurs through 
transcriptional activation (Song et al. 1986). 
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Transcriptional activation of CYP2Cll in male rats does not 
occur until puberty but is dependent on both neonatal and 
adult exposure to androgens. The female specific CYP2Cl2 is 
expressed in both male and female rats before puberty but is 
not expressed in adult rats (Gonzalez et al. 1986). Another 
type of control occurs for rat CYP3A2 which is expressed at 
10w levels in prepubital males and females and in adult males 
but is not expressed in adult females. The decrease in 
protein levels in females is associated with a decrease in 
mRNA for CYP3A2 (Waxman et al. 1985). 
Regulation of CYPlAl and 1A2 by aryl hydrocarbons has 
been more thoroughly studied than that of other cytochromes 
P450. Induction of CYPlAl proteins is genetically controlled 
by the aryl hydrocarbon (Ah) locus (Lambert and Nebert 1977, 
Nebert 1977) and is initiated when a ligand such as 2,3,7,8 
tetrachlorodibenzo-p-dioxin (TCDD) binds to the Ah receptor. 
The receptor ligand complex is translocated into the nucleus 
by the Arylhydrocarbon Receptor Nuclear Translocator (ARNT) 
protein (Hoffman et al. 1991). Other proteins, including the 
Arylhydrocarbon Ligand Binding Subunit (ALBS) and a 90-kDa 
heat shock protein are also part of the Ah receptor before 
ligand binding. Both the ARNT and ALBS subunits have been 
purified (Hoffman et al. 1991, Burbach et al. 1992). When a 
ligand such as TCDD binds to the receptor complex the heat 
shock protein dissociates and the ligand-receptor complex is 
translocated into the nucleus. Transcription of CYPlA mRNA 
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increases when a specific DNA sequence (the xenobiotic 
response element or XRE) in the S' regulatory region of the 
CYPlA gene is bound to the ligand-receptor complex. In 
response, mRNA for CYPlA and ultimately enzyme level and 
activity in the endoplasmic reticulum are increased (Nebert 
and Gonzalez 1987). 
The structure and function of the Ah receptor has been 
compared to that of the steroid receptor family (Whitelaw et 
al. 1993, Landers and Bunce 1991). Both types of receptors 
are associated with the 90-kDa heat shock protein and this 
complex dissociates on binding with the respective ligand. 
Another similarity to steroid hormones receptor dependent 
activation is that formation of the receptor ligand complex is 
not sufficient for activation. That is, the complex undergoes 
additional changes before it becomes functionally active 
(Landers and Bunce 1991). Another similarity to steroid 
receptors is that TCDD can bind to the estrogen, 
glucocorticoid and prolactin receptors (Landers and Bunce 
1991). 
One difference is that the steroid receptors contain zinc 
finger motifs while both ARNT and ALBS contain a basic helix-
loop-helix motif. It has been postulated that these different 
structures have similar regulatory functions. The retinoid X 
receptor is a zinc finger receptor that binds with other 
receptors in the zinc finger steroid receptor family, and acts 
as a coregulator. ARNT acts as a coregulator with ALBS and 
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the two proteins apparently associate through the basic helix-
loop-helix structure (Whitlaw et al. 1993). 
Other types of CYP gene regulation occur in different CYP 
families. Phenobarbital induces both CYP2 and CYP3 enzymes. 
The mechanisms of induction for the two CYP families are 
different as shown by three types of studies. In primary 
hepatocyte culture, a twenty fold higher dose of phenobarbital 
is required to induce CYPJA enzymes as compared to CYP2 
enzymes (Kocarek et al. 1990). In another study, 
cycloheximide added to hepatocytes in primary culture to block 
protein synthesis, blocks phenobarbital induction of CYP2 
proteins but enhances phenobarbital induction of CYPJA several 
fold (Burger et al. 1990). In situ hybridization with probes 
for CYP2B1/2 and for CYP3A mRNA indicates that not all CYPs 
are induced in the same cells following treatment with 
phenobarbital. For example, mRNA for CYP2B1 and 2B2 increases 
in all liver cells except in the periportal region, while mRNA 
for CYP3Al and 3A2 increases only in the centrilobular region 
(Omiecinski et al. 1990). This tissue specific induction also 
indicates different mechanisms of phenobarbital induction for 
different CYP proteins. 
Al though the mechanism by which phenobarbital induces CYP 
proteins is not known, a receptor mechanism may be involved 
for CYP2B1 and 2B2. Two characteristics of a receptor 
mechanism are a structure activity relationship for a series 
of chemicals and a dose response curve for increasing 
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concentrations of an inducer. Both of these characteristics 
have been observed for a series of polychlorinated biphenyls 
that have phenobarbital-like inducing characteristics (Denomme 
et al. 1983). However, phenobarbital may act indirectly to 
induce CYP2C6, 2Bl and 2B2 because rat hepatoma cells that 
retain the capacity to increase CYP2C6 mRNA and protein when 
treated with dexamethasone (dex) or with phenobarbital respond 
differently to the two treatments. Messenger RNA for CYP2C6 
increases within four hours after treatment with dex but not 
until twelve hours after treatment with phenobarbital. 
Induction by either dex or phenobarbital could be prevented by 
blocking transcription or protein synthesis or by treating the 
cells with RU486, a glucocorticoid-progesterone antagonist 
(Shaw et al. 1993). 
Protein binding to a seventeen base sequence in the 
upstream region of CYP2Bl and 2B2 is involved in phenobarbital 
regulation of these enzymes. A protein that is present in 
hepatic nuclear extracts prepared from rats treated with 
barbiturates but not from untreated rats binds to this 
seventeen base sequence. A different protein that is present 
in untreated Bacillus megaterium but not in phenobarbital 
treated B. megaterium binds to the same sequence in the 
regulatory region of two prokaryotic barbiturate inducible 
proteins, P4S08M_ 1 and P4508M_ 2 (He and Fulco 1991). 
Both of these reports are consistent with an indirect 
effect of phenobarbital on CYP2Bl and 2B2 levels with 
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synthesis of a protein required before induction occurs. The 
effect of RU486 could be either to block synthesis of the 
protein or to bind to the protein and prevent its inducing 
effect. The effect of the antiprogestin-antiglucocorticoid 
suggests the protein could be part of the steroid receptor 
family or a protein that interacts with a steroid receptor. 
In addition to transcriptional regulation of CYP protein 
levels, post-transcriptional regulation can occur. Gender and 
tissue specific regulation of CYP2El levels in mouse kidney 
occur because testosterone increases CYP2El mRNA without 
increasing the transcription rate (Pan et al. 1992). 
Regulation of cytochrome P450s and Substrate Toxicity 
Agents that bind to the Ah receptor can induce CYPlAl and 
1A2 cytochrome P450s and therefore alter the relative 
abundance of these P450s and of their metabolic products. For 
example indole-3-carbinol increases the P450 dependent 
formation of estrogen 2a-hydroxylate and decreases the 
formation of the 16a-hydroxylase metabolite (Jellinek et al. 
1993) . This change in metabolic pathway is significant 
because the 16a-hydroxyestrone is associated with an increase 
in mammary tumor incidence in tumor susceptible mice (Bradlow 
et al. 1991). 
The cytochrome P450s may have fundamental physiological 
roles because many of these enzymes have an endogenous 
substrate that is associated with growth and differentiation 
(Nebert 1991). A drug or xenobiotic could be toxic because 
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it mimics an endogenous factor that acts through a receptor 
mediated mechanism. A substance that binds to a receptor for 
an endogenous ligand could have the same effect as increasing 
the level of the endogenous ligand and thereby initiating a 
regulatory mechanism designed to correct the inappropriate 
"ligand" level. Thus TCDD could be toxic because it acts like 
a physiological ligand of the Ah receptor and alters the 
regulatory effect of that ligand (Nebert 1991). 
Testosterone Metabolism in Mice 
In mice, testosterone is metabolized by several different 
regiospecific and stereospecific hydroxylases including 
enzymes that are specific for positions 6P, 15a, 15P, 16a and 
16P (Ford et al. 1975). Male and female mice have specific 
hydroxylase activities but at different levels and with 
differences among mouse strains (Ford et al. 1979). 
At least three CYP2 subfamilies have testosterone 
hydroxylase activity and different proteins within the same 
subfamily can be regulated in tissue or gender specific 
patterns. Testosterone 15a-hydroxylase activity is higher in 
female liver as compared to male. The opposite pattern occurs 
in kidney where the male has higher activity ( Squires and 
Negishi 1988, 1990). There are two proteins with 15a 
activity, originally designated P45015a type I and type II, now 
named CYP2A4 and 2A5. The enzymes also have 15a hydroxylase 
activity for progesterone and dehydroepiandrosterone (Harada 
and Negishi 1988). Although there are only eleven amino acid 
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differences between CYP2A4 and CYP2A5, the mRNAs for the two 
proteins can be distinguished because there is a unique Pstl 
site in CYP2A5. CYP2A4 mRNA is the major form in male mouse 
kidney while both CYP2A4 and 2A5 are expressed in the liver 
(Squires and Negishi 1990). 
Two CYP2 subfamilies have testosterone 16a-hydroxylase 
activity, the female predominant CYP2B (I-P-45016a) and the 
male predominant CYP2D (C-P-45016a), (Noshiro et al. 1988, Wong 
et al. 1989). CYP2B is induced by phenobarbital in female and 
male 129/J mice (Devore et al. 1985). 
Testosterone 6,B-hydroxylase activity is supported by 
hepatic microsome prepared from male or female mice (Ford et 
al. 1975, 1979), and by a protein purified from untreated male 
mice (Bornheim and Correia 1990). The N-terminal amino acid 
sequence is more than 80% homologous with rat CYP3Al and 3A2. 
A cDNA that encodes a protein with the same N-terminal amino 
acid sequence is also in the CYP3A subfamily (Yanagimoto et 
al. 1992). 
Hormonal Regulation of Testosterone Metabolism 
Growth hormone has different regulatory effects on 
specific CYP proteins, especially on the gender specific 
expression of testosterone hydroxylases in mouse and rat. 
This gender specific regulation of P450 induction has been 
related to the gender differences in growth hormone secretion. 
In females, growth hormone secretion rates and plasma levels 
vary within a narrow range and increases are irregularly 
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spaced over a twenty four hour period, but in males there are 
very sharp regularly spaced increases followed by decreases to 
almost undetectable plasma levels (Eden 1979, Mode et al. 
1988). 
owarf mice, referred to as Little, are especially useful 
for examining the effects of growth hormone on gene regulation 
because their only defect is an autosomal recessive mutation 
that produces decreased serum growth hormone levels but normal 
levels of other pituitary hormones. (Phillips et al. 1982). 
The lit/+ heterozygotes have the same gender dependent pattern 
of hepatic microsomal testosterone metabolism as the C57BL/6J 
parent strain. For the lit/lit homozygotes there are no 
gender differences for testosterone hydroxylation at either 
the 15a or the 16a position (Noshiro and Negishi 1986). 
Testosterone 15a-hydroxylase activity is increased in both 
males and females as compared to the heterozygote lit/+ 
controls. Growth hormone administered twice daily represses 
expression of the female specific CYP2B in both male and 
female mice (Noshiro and Negishi 1986). 
Although in vivo treatment of Little mice can demonstrate 
a positive regulatory effect for growth hormone, the effect 
could be on some organ system other than the liver. 
Therefore, hormone treatment of primary hepatocyte cultures 
has been used to test for direct effects on the cell by 
individual hormones or combinations of hormones. Primary rat 
hepatocytes in a monolayer culture on a reconstituted basement 
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membrane retain many of their differentiated functions 
including the capacity to respond to treatment by increasing 
p450-specific mRNA and protein synthesis (Schuetz et al. 
1988). 
Growth hormone can act directly on the hepatocyte for the 
sexually differentiated rat CYP2C subfamily. There are five 
members in this subfamily, CYP2Cll and 2Cl3 are male specific, 
CYP2C7 and 2C12 are female specific, and CYP2C6 is expressed 
at comparable levels in liver tissue from male and female 
rats. Expression of the male specific P450s in hepatocytes 
prepared from male rats and incubated in the presence of 
continuous growth hormone is decreased to 50% or less of the 
level in control hepatocytes with no growth hormone (Liddle et 
al. 1992). This is consistent with in vivo experiments in 
which growth hormone treatment of hypophysectomized rats 
induces the gene for CYP2Cl2 and represses the genes for 
CYP2Cll and 2Cl3 as determined by nuclear run-on analysis 
(Legraverend et al. 1992). 
steroid hormones can regulate some P450s including those 
in the rat CYP2C subfamily. Hepatic levels of the female 
specific CYP2C7 were decreased in neonatally ovariectomized 
females as compared to sham operated animals and could be 
restored to the level of the sham operated animals by 
estrogen .. Similarly the male specific CYP2Cll is decreased in 
neonatally gonadectomized male rats and can be restored to the 
level in sham operated rats by treating the adults with 
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testosterone (Bandiera and Dworschak 1992). 
Androgens have tissue specific and enzyme specific 
effects on the expression of mRNAs for two mouse P450s. 
CYP2A4 mRNA is increased but CYP2A5 mRNA is not changed in 
male liver from castrated as compared to normal males. In the 
male kidney, mRNA for CYP2A5 is decreased in the absence of 
androgens (Squires and Negishi 1990). Another mouse 
cytochrome P-450 has a similar tissue specific testosterone 
dependent regulation. Female mice chronically treated with 
testosterone have increased kidney mRNA and decreased liver 
mRNA that hybridizes to a CYP2El specific probe as compared to 
untreated females. There is only low sequence identity between 
CYP2El and the CYP2As (Voliva and Paigen 1991). 
In rats, treatment with the reduced progesterone 
derivatives pregnanolone and pregnanediol has a similar effect 
as pregnancy on several enzyme activities, that is, it 
decreases aminopyrine N-demethylase, and coumarin-3-
hydroxylase. Pregnenolone-16a-carbonitrile and 16a-hydroxy-
progesterone had the opposite effect in that they increased 
both enzyme activities in hepatic microsomes of treated rats 
(Feuer 1979). 
Cytochrome P450 Family 3 
The first enzyme in the CYP3 family to be identified as 
a new protein was induced in rat liver by treatment with the 
synthetic steroid pregnenolone-16a-carbonitrile (PCN). This 
protein was originally named P450PCN (Elshourbagy and Guzelian 
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Table 1. Homology of CYP3A cDNA Sequences. Sequence 
identities among CYP3A members from different species were 
calculated from the GCG data base using GCG GAP. When more 
than one 3A subfamily from a species are known, they are in 
adjacent rows and columns. Abbreviations used are monk = 
monkey, rabt = rabbit and hmst = hamster. Nucleotide sequence 
homologies between these members of the CYP3A subfamily are 
shown in table 1. Sequence homology can be very high 
especially within a species as shown by the four human CYP3As. 
The homology between two CYP3A members may not be evenly 
distributed along the molecule as has been reported for rat 
CYP3Al and 3A2 as discussed above. 
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Table 1 
Homology of CYP3A cDNA Sequences 
mouse rat human monk rabt dog hmst 
3All 3Al3 3Al 3A2 3A3 3A4 3A5 3A7 3A8 3A6 3Al2 3A10 
3All 100 
3Al3 76 100 
3Al 89 76 100 
3A2 88 77 90 100 
3A3 76 80 73 73 100 
3A4 76 79 71 71 99 100 
3A5 77 79 75 75 88 88 100 
3A7 76 80 75 72 92 93 88 100 
3A8 75 76 74 71 94 93 88 95 100 
3A6 77 79 72 73 76 76 80 77 77 100 
3Al2 75 80 68 68 83 75 81 76 76 74 100 
3A10 73 71 71 70 71 71 74 72 71 69 67 100 
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19ao). A related protein that is not induced by PCN but is 
constitutively expressed in adult male and in prepubertal rats 
was named P450PCN2 (Gonzalez et al. 1985) . In the new 
nomenclature P450PCN1 is named CypJAl and P450PCN2 is named 
cypJA2. There is 89% amino acid and 90% nucleotide sequence 
identity between these two rat proteins (Gonzales et al. 1985, 
Gonzales et. al 1986). There are four human genes with 
sequences that place them in the CYPJA subfamily. They have 
been designated CYPJAJ (originally HLp, Watkins et al. 1985), 
CYP3A4 (P-450NF' Beaune et al. 1986), CYPJA5 (P-450 hPCNJ, 
Aoyama et al. 1989) and CYPJA7 (HFLa, Kitada et al. 1987). 
The CYPJA subfamily sequences from other species have been 
given separate names including CYPJA6 from rabbit (P450 Jc, 
Dalet et al. 1988), CYPJA8 from monkey (MKnf2, Ohta et al. 
1989), CYPJAl0 from hamster (Teixeira and Gil 1991), CYPJAll 
(IIIAml, Yanagimoto et al. 1992) and JA13 (Yanagimoto 1991 
GenEMBL X63023) from mouse, and CYPJA12 from dog (PBD-1 
Ciaccio et al. 1991). The systematic names are from Nelson et 
al. (1993). 
Xenobiotic Substrates of CYP3A Enzymes 
A specific method to determine the substrates of an 
enzyme is to purify the protein and measure metabolic activity 
toward possible substrates. This is difficult to do for 
cytochrome P450s because enzymatic activity is lost when the 
protein is removed from its lipid environment. When the 
purified P450 protein is suspended in lipid, activity can be 
26 
restored if NADPH-dependent cytochrome P450 reductase and 
cytochrome b 5 are also included (Halvorsan et al. 19.90). 
cYP3A enzymes are especially difficult to reconstitute because 
the lipid must be either microsomal lipid extract (Halvorsan 
et al. 1990) or a mixture of lecithin and phosphatidylserine. 
(Imaoka et al. 1988). 
CYP3A metabolizes a large number of xenobiotic compounds 
with different structures including macrolide antibiotics, the 
macrocyclic peptide cyclosporine and the calcium channel 
blocker nifedipine. Although the only structural similarity 
among these substrates is that they are lipophilic there are 
only a few types of reactions that are supported, usually 
aliphatic oxidation and N-dealkylation (Smith and Jones 1992). 
cyclosporin, lovastatin, 111-tetrahydrocannabinol and quinidine 
are each hydroxylated in an allylic position. Apparently the 
binding site is flexible because cyclosporin can be 
hydroxylated at three different sites each with the same 
allylic structure (Smith and Jones 1992). Examples of CYP3A 
substrates that are metabolized by N-demethylation include 
codeine, verapamil, dextromethorphan, ethylmorphine, 
tamoxifen, erythromycin and triacetyloleandomycin (TAO). 
The macrolide antibiotics are a particularly interesting 
group of xenobiotic substrates for CYP3A enzymes because of 
their large size and because specific examples can inhibit 
CYP3A dependent metabolism (Pessayre et al. 1981). The 
macrolide antibiotics with the capacity to inhibit CYPJA 
27 
activity such as TAO contain a secondary or tertiary amine on 
a deoxy sugar which is attached to a large lactone ring (Sanae 
and Mandel 1985). When one methyl group is removed a stable 
inactive enzyme complex that cannot react with molecular 
0 xygen is formed. The metabolic complex, which can be 
measured because of its strong absorbance at 456nm, can be 
displaced by treatment with potassium ferricyanide to restore 
CYPJA activity (Delaforge et al. 1984). The N-demethylation 
of the macrolide antibiotic is a CYPJA dependent reaction and 
changes in the in vivo or in vitro formation of the metabolic 
intermediate indicates changes in the quantity of CYPJA 
protein (Wrighton et al. 1985). Inhibition of a reaction by 
TAO indicates that a CYPJA protein is catalyzing the reaction 
(Namkung et al. 1988) . Erythromycin is another macrolide 
antibiotic metabolized by CYPJA but no metabolic complex is 
formed with this substrate (Watkins et al. 1989). 
Endogenous Substrates of CYP3A Enzymes 
The steroid hormones testosterone and progesterone are 
metabolized by CYPJA by hydroxylation at the 6P position, the 
only allylic position in each molecule. However this is not 
the only position oxidized by CYPJA. Reconstitution of CYP3Al 
in a purified microsomal lipid or in a mixture of lecithin and 
phosphatidyl serine will restore testosterone hydroxylase 
activity (Halvorson et al. 1990, Imaoka et al. 1988). When 
purified, reconstituted CYP3Al metabolizes testosterone, 51% 
of the metabolic product is 6P-hydroxytestosterone. The 
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remainder of the metabolites are 2j3-hydroxytestosterone (18%), 
1sp-hydroxytestosterone {11%), and 6-dehydrotestoste·rone 
(10%), (Halvorson et al. 1990). Each of these reactions in 
hepatic microsomes prepared from adult female or fetal rats 
can be inhibited by TAO (Namkung et al. 1988). Progesterone 
is also a substrate for CYP3A enzymes in humans (Waxman et al. 
1991), and in rats (Swinney et al. 1987). Estradiol 
hydroxylation at the two and four positions is a CYP3A 
dependent reaction in adult female rats {Namkung et al. 1988). 
Al though the majority of CYP3A proteins have testosterone 
6P hydroxylase activity there are specific examples that 
metabolize other types of substrates. The endogenous 
substrate for CYP3Al0 is lithocholic acid, a toxic bile acid 
that is increased in serum during cholestasis. Hepatic 
lithocholic acid 6P-hydroxylase activity is induced in 
hamsters fed cholic acid as compared to chow fed hamsters. The 
cDNA for the 6P-hydroxylase places the enzyme in the CYP3A 
subfamily with overall nucleotide sequence homology with rat 
CYP3As of 81% (Teixeira and Gil 1991). 
Rat hepatic microsomes have lithocholic acid hydroxylase 
activity but CYP3Al and 3A2 do not appear to be the P450s with 
that activity. When metabolic activity in hepatic microsomes 
from control and induced male and female rats were compared, 
lithocholic acid 6P-hydroxylase and androstenedione 6P 
hydroxylase activities were induced to different degrees by 
each of the inducers phenobarbital, dexamethasone or 
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clofibrate (Zimniak et al. 1990). The P450 with lithocholic 
acid 6/3 hydroxylase activity could be a different CYPJA 
because rabbit polyclonal antibodies to 3Al inhibited rat 
hepatic microsomal lithocholic acid 6/3 hydroxylase activity. 
Indirect evidence for lithocholic acid hydroxylation by a rat 
CYPJA enzyme can be found by sequence comparisons. At least 
four enzymes with testosterone 6/3 hydroxylase activity have 
been purified from rat liver (Nagata et al. 1990). For one of 
these, P4506~_ 2 , the twenty seven N-terminal amino acid 
sequence has 85% identity to CYPJAlO as compared to 51% amino 
acid identity to the same region of CYP3Al or 3A2. 
The biological activity of retinoic acid is terminated by 
oxidation to retinoic acid 4-hydroxide. In rat hepatic 
microsomes this oxidation is supported by CYP3Al or a closely 
related protein as shown by the capacity of antibodies to 
CYP3Al to inhibit this oxidation. Antibodies to P450s in 
other families do not inhibit retinoic acid 4-hydroxylase 
activity in these microsomes (Martini and Murray 1993). 
Retinoic acid 4-hydroxylase activity in rat hepatic microsomes 
is induced during development in the same pattern as CYP3A2, 
that is, the activity is present in hepatic microsomes from 
one week old rats of either gender but increases with age in 
male rats only so that at ten weeks the activity in male rat 
hepatic microsomes is greater than in female hepatic 
microsomes. 
Another reaction that may be supported by a CYPJA protein 
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is part of the synthesis of nitric oxide from L-arginine which 
involves enzymes that are similar to cytochrome P-450s in.that 
they require NADPH and 0 2 • Induction of rat CYP3A by dex, 
TAO or phenobarbital increases the rate of cleavage of N11 
hydroxy-L-arginine in the second step of NO synthesis. The 
reaction can be inhibited by two specific inhibitors of CYP3A 
activity, TAO and dihydroergotamine (Renaud et al. 1993). 
Nitric oxide biosynthesis increases during gestation in 
maternal rats by a pathway that is inhibited by NG-
nitroarginine methyl ester, a specific inhibitor of NO 
synthase (Conrad et al. 1993). 
Induction of Specific P450s 
Cytochrome P450s are found in every tissue examined, but 
both total enzyme level and specific P450 content vary. The 
liver has the highest level of total P450 although levels of 
specific P450s may be higher in other tissues. Specific 
cytochrome P450 proteins may be expressed constitutively while 
other P450s are expressed only after treatment with any one of 
a large number of drugs or other chemicals. Some of the 
constitutively expressed P450s are also inducible. 
There are at least five types of inducers of cytochrome 
P450s, including 1. aryl hydrocarbons such as 3-methylchol-
anthrene, 2. phenobarbital and some polychlorinated biphenyls 
3. isosafrole, 4. pregnenolone 16a-carbonitrile and 5. 
clofibrate or ethanol (Delaforge and Sartori 1990). Induction 
is usually specific in that only one or a few CYP subfamilies 
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is induced by a given treatment. However Phase II enzymes 
such as UDP-glucuronosyl transferase, epoxide hydrolase or 
glutathione-S-transferase may be induced along with the 
cytochrome P450 (Nebert 1991). 
xenobiotic Regulation of CYPJA Protein 
cytochrome P450 family 3 is induced by four mechanistic 
types of inducers (Okey 1990). One type includes the 
antiglucocorticoid, pregnenolone 16a-carbonitrile. This 
inducer type also includes the glucocorticoid dexamethasone 
and the mineralcorticoid spironolactone. Another type of 
inducer includes macrolide antibiotics such as TAO, 
erythromycin and rifampicin. The inducer type that includes 
phenobarbital and other chemicals with phenobarbital-like 
regulatory action such as the organochlorine pesticides and 
polychlorinated biphenyls also induce some CYP3As. A fourth 
group of chemicals that induce CYP3As include the imidazole 
fungicides such as clotrimazole and ketoconazole. Different 
cytochrome P450 3As may not be induced to the same extent by 
all of these compounds. 
The earliest studies of substrate specific induction of 
the enzymes in the CYP3A subfamily were carried out in the rat 
using an increase in mRNA as the criteria for induction 
(Gonzalez et al. 1986). CYP3Al mRNA is induced by dex and by 
phenobarbital while CYP3A2 mRNA is not induced by either 
steroid but is induced by phenobarbital. More recently, 
Cooper et al. (1993) developed monoclonal antibodies specific 
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for each of these two proteins with less than five percent 
cross reactivity with the other protein. Using the patte:;:-n of 
induction by xenobiotic substrates, as detected by these 
monoclonal antibodies, they divided CYP3A inducers into two 
classes based on the relative induction of the two proteins. 
Each of these two classes of inducers include examples from 
more than one of the types listed above. The class of 
inducers that increase both 3Al and 3A2 includes TAO, PCN and 
dex. These inducers increase the level of the total of CYP3Al 
and 3A2 to 40% of the total hepatic microsomal P450 in adult 
male rats while maintaining a two to one ratio of CYP3Al and 
CYP3A2. Both rate of transcription and protein stabilization 
are increased by this class of CYPJ inducers (Simmons et al. 
1987, Delaforge and Sartori 1990). Intranuclear pre-mRNA and 
cytoplasmic RNA levels increase several fold more than the 
increase in the rate of transcription indicating that post 
transcriptional regulation of CYP3As by PCN or Dex also occurs 
(Simmons et al. 1987). The other class of CYPJA inducers 
increases the expression of one 3A protein more than the 
other. This class includes rifampicin, phenobarbital and 
Arochlor 1254 that increase CYP3Al expression and 3-
methylcholanthrene that increases CYP3A2 expression. 
Endogenous Regulation of CYP3A Proteins 
In the rat the levels of the two identified CYPJA 
proteins differ in a gender specific manner. CYP3Al protein 
is not detected in the liver of untreated male or female rats 
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of any age as measured by the epitope specific antibody that 
reacts with CYP3Al but does not react with CYP3A2 prqtein 
(Cooper et al. 1993). CYP3A2 occurs in both immature male and 
female rats but only mature male rats. This gender and 
inducer dependent pattern has also been reported for mRNA 
levels for these two proteins (Omiecinski et al. 1990, 
Gonzalez, Song and Hardwick 1986). Pregnancy does not induce 
cYP3A protein or the CYP3A dependent activity debenzylation of 
benzyloxyphenazone in rat hepatic microsomes al though the 
CYP3A protein can be induced by PCN treatment in both dams and 
fetuses (Hulla and Juchau 1989). Lactation, but not 
pregnancy, induces CYP3Al mRNA in rats ( Borlakoglu et al. 
1993) 
The CYP3A specific reaction testosterone 6/3-hydroxylation 
is undetectable in hepatic microsomes from new born rats but 
increases during maturation until puberty in both male and 
female rats. At puberty the enzymatic activity increases 
further in male rats but decreases to an almost undetectable 
level in adult female rats (Gonzalez et al. 1986). 
Testosterone 6/3-hydroxylation is sharply decreased or absent 
in 24 month old male rats (Robinson et al. 1990, Imaoka et al. 
1991) . 
The gender and age related changes in CYP3A content and 
activity have been related to differences in hormone status of 
the rats (Waxman 1988) . Hypophysectomy increases hepatic mRNA 
for CYP3A2 in both male and female rats to the same level. 
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Intermittent injection of human growth hormone decreases the 
mRNA levels for both CYP3Al and 3A2 to the level in normal 
male rats and 
hybridizing mRNA 
continuous infusion almost eliminates 
(Waxman et al. 1988, Yamazoe et al. 1988). 
A role for testosterone in regulating rat CYP3Al/3A2 has 
been demonstrated. Streptozotocin-induced diabetes increases 
serum glucose levels, and decreases serum testosterone and 
peak growth hormone levels in male rats. Hepatic microsomal 
CYP3Al/3A2, measured by a monoclonal antibody that recognizes 
both forms, is decreased in diabetic male rats. Testosterone 
treatment restores the level of protein recognized by the 
antibody to the normal male level more effectively than 
intermittent growth hormone. 
restore the male pattern 
Testosterone treatment does not 
of serum growth hormone 
concentrations (Thummel and Schenkman 1990). 
In primary culture, growth hormone blocks induction of 
CYP3Al mRNA by phenobarbital 75 to 80% and blocks induction by 
dex or PCN but to a lesser extent. This is not a general 
effect of growth hormone on mRNA because the levels of mRNA 
for NADPH dependent P450 reductase, tyrosine aminotransferase 
(TAT) or albumin are not affected by the presence of growth 
hormone in the culture (Schuetz and Guzelian 1984). 
Synthetic glucocorticoids including PCN and dex induce 
CYP3A protein by increasing the rate of transcription and by 
message or protein stabilization (Simmons et al. 1987b). A 
single dose of either of the synthetic glucocorticoids 
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increases the transcription rate for CYP3A without altering 
the transcription rate for RNA for other proteins involved in 
drug metabolism including P450b, a phenobarbital induced P450, 
and the NADPH-dependent P450reductase. Dexamethasone can 
induce CYP3A in primary hepatocyte culture indicating that the 
glucocorticoid can act directly on the hepatocyte (Schutz et 
al. 1984). Glucocorticoids stimulate synthesis of TAT by the 
classical mechanism of binding to a cytosolic receptor, 
translocation into the nucleus, binding to DNA and increasing 
gene transcription. Induction of CYP3A by Dex or PCN does not 
appear to follow this classical pathway because CYP3A 
induction is later than TAT induction and a higher 
concentration of the glucocorticoid is required for CYP3A 
induction than for TAT induction. In addition PCN induces 
CYP3A but does not induce TAT while spironolactone induces 
CYP3A but inhibits TAT synthesis (Schuetz and Guzelian 1984). 
Cytochrome P450gest 
cytochrome P450gest was identified in a study of the 
effect of pregnancy in the mouse on total cytochrome P450 and 
the rate of metabolism of two substrates (Lambert et al. 
1987) . Hepatic P450gest content in pregnant female mice 
increases at about the time of implantation but decreases in 
late gestation as compared to virgin female mice. However the 
in vitro rate of metabolism of aminopyrine decreases 
throughout gestation while ethylmorphine metabolism remains 
unchanged. The HPLC profile of hepatic P450s indicates that 
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some P450s could be decreasing during gestation but also 
demonstrates induction of at least one heme containing 
protein. The protein has the spectral properties of 
cytochrome P450. 
sormonal Effects of Pregnancy 
Serum levels of both steroid and protein hormones are 
altered during pregnancy and lactation in the mouse as in 
other mammals. 
the first two 
Plasma levels of progesterone are low during 
days of gestation, rise steadily through 
gestation day six and remain high through day seventeen, then 
drop to prepregnant levels just before parturition (McCormick 
and Greenwald 1974). Estrogen levels start at a high level, 
drop to about 40% of the early level until gestation day 
seventeen when the level returns to the early gestation levels 
or slightly higher (McCormick and Greenwald 1974). Plasma 
corticosterone levels rise slowly during the first ten days of 
gestation followed by a steep 15 fold increase by day sixteen 
and then drop to the gestation day ten level the day after 
parturition (Barlow et al. 1974). Serum corticosteroid-
binding-globulin also increases so that the serum 
concentration of unbound corticosterone decreases at mid 
gestation, but rebounds to a level above that in the virgin by 
late pregnancy. The level of unbound corticosterone continues 
to increase during lactation to about four times the level in 
virgin mice by late lactation (Gala and Westphal 1967). 
Prolactin occurs in mouse serum in three forms, 
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monomeric, dimeric and polymeric and both form and 
concentration change during gestation. In female virgin_mice 
serum prolactin is primarily in the monomeric form while in 
male mice it is primarily in the polymeric form and is present 
at only 7% the level of female mice. During pregnancy, serum 
prolactin levels decrease by 16% and during lactation there is 
a further decrease to 60% of serum level in virgin mice (Sinha 
1968). 
circulating growth hormone in the monomeric form makes up 
33% of the total in adult virgin female mice but is only 13-
15% of the total in male or pregnant female mice. At eighteen 
to twenty days gestation in C57BL/St mice serum growth hormone 
levels are double the levels present in mice in other hormonal 
states including nonpregnant or lactating female mice and male 
mice (Sinha 1968). 
Regulation of Mouse Mammary Gland Development 
The induction of P450gest during both pregnancy and 
lactation suggests that hormones necessary for mammary gland 
maturation could also have a role during induction of the 
hepatic protein. 
Growth and differentiation of mammary gland epithelial 
cells during pregnancy and maintenance of the differentiated 
cells and lactogenesis require the presence of a combination 
of steroid and hypophysial hormones (Nandi 1958, Borrellini 
and Oka 1989). Lactation equivalent to that in twelve day 
postpartum mice can be induced in hypophysectomized-
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0 variectomized-adrenalectomized virgin female mice by a two 
stage treatment with a combination of hormones. The first 
stage of the treatment includes J3-estradiol, progesterone, and 
cortisol acetate plus growth hormone and prolactin and the 
second stage includes cortisol acetate, growth hormone and 
prolactin. Treatment with both prolactin and growth hormone 
with the three steroids was a more effective inducer of 
lactogenesis than treatment with either one of the peptides 
with the combination of steroid hormones (Nandi 1958). 
Insulin, prolactin and glucocorticoid can induce mammary gland 
development in whole organ culture or differentiation of 
epithelial cells in culture only when the donor animal was 
pretreated with estrogen and progesterone (Borrellini and Oka 
1989). 
CYP3A Activity in Mice 
CYPJA dependent activity has been demonstrated in female 
OBA/2 mice by two types of activity, TAO complex formation and 
ERNO activity (Wrighton et al. 1989). Unlike the rat where 
the untreated male has high ERNO activity, untreated male 
mouse hepatic microsomes have no ERNO activity but can form a 
complex with TAO. Untreated female mouse liver microsomes 
have measurable ERNO activity and can form the TAO complex. 
This suggests that different CYP3A proteins are involved in 
ERNO activity as compared to TAO complex formation (Wrighton 
et al. 1985). 
In another study, cannabidiol was used as a specific 
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inhibitor of CYP3A dependent activity in male and female CF-1 
mice. In this mouse strain, hepatic microsomes prepared from 
male mice had approximately a two fold higher ERNO activity as 
compared to microsomes prepared from female mice. Cannabidiol 
inhibits a larger fraction of the ERNO activity in male mouse 
microsomes so that after in vivo cannabidiol treatment the 
ERNO activity was approximately equivalent in microsomes 
prepared from male and female mice ( Bernheim and Correia 
1990). Oexamethasone treatment of male CF-1 mice induced P450 
content and the CYP3A dependent metabolic activities 
testosterone 6/3 hydroxylation and ERNO activity six fold. 
However the induced activity was not inhibited by cannabidiol 
suggesting the presence of at least two CYPJA enzymes index 
treated male CF-1 mice (Bernheim and Correia 1990). 
Cannabidiol inhibits the ERNO activity induced by 
phenobarbital but not the activity induced by dex implying 
that the cannabidiol inhibits a specific CYP3A protein but has 
no effect on other proteins in the subfamily. 
Testosterone 6/3-hydroxylase activity is supported by 
hepatic microsomes from male and female mice (Ford et al. 
1975, 1979). A protein purified from untreated male mice (CF-
1) has high testosterone 6/3 hydroxylase activity with lower 
activity at the 2a and 15/3 sites. The sequence of the twenty 
four N-terminal amino acids is more than 80% homologous with 
rat CYP3Al and CYP3A2 and therefore the mouse protein has been 
named AmIIIur (Bernheim and Correia 1990). The complete amino 
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acid sequence deduced from a cDNA isolated from dex treated 
male ddY mice has the same amino terminal sequence as AmlIIuy• 
This amino acid sequence is 90.3% homologous with rat CYPJAl 
and 89.0% with CYPJA2 (Yanagimoto et al. 1992). 
Methods 
Animal care 
C57BL/6J mice (Jackson Laboratories, Bar Harbor, Maine) 
were maintained in a temperature and humidity controlled 
environment with a twelve hour light/dark cycle. Food and 
water were offered ad libitum. Female mice were housed four 
per cage. To obtain timed-pregnant mice, one male was added 
to a cage overnight. Females were checked for vaginal plugs 
the following morning and the male was removed from the cage 
for several days. The day the plug was observed was 
considered day O of pregnancy. Females with vaginal plugs 
were housed together until gestational day seventeen when they 
were moved into separate cages. 
Preparation of Hepatic Microsomes 
Hepatic microsomes were prepared by homogenizing the 
liver in 1.15% KCl with a Teflon pestle glass homogenizer. 
The homogenate was centrifuged at 9000 x g to remove nuclei 
and cellular debris. This supernatant fraction was 
centrifuged at 100,000 x g for one hour at 4°C. The 
microsomal pellet was suspended in 20% (vol/vol) glycerol in 
a 10 mM solution of potassium phosphate (pH 7. 4) 10 mM 
ethylenediaminetetraacetic acid disodium (EDTA) , and 1 mM 
dithiothreitol (OTT) and stored at -70°C. Thawed microsomes 
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were prepared for HPLC by diluting with 1. 15% KCl and 
centrifuging at 100,000 x g for one hour. The micros.omal 
pellet was solubilized in a 10 mM potassium phosphate buffer 
(pH 7.4) which contained 20% glycerol, 0.2% Emulgen 911 (Kao 
corporation Tokyo, Japan), 0.5% cholic acid, and 0.1 mM EDTA 
(Kotake and Funae 1980). Microsomal protein concentration was 
measured by the method of Lowry et al. (1951) using bovine 
serum albumin fraction V as the standard. The solubilized 
protein concentration was adjusted to 5 to 10 mg protein/ml. 
Total cytochrome P450 content was measured by the method of 
Omura and Sato (1964). 
cytochrome P450 HPLC Profile 
Cytochrome P450s in hepatic microsomes were separated by 
HPLC using a Perkin Elmer Liquid Chromatograph Series 2 pump 
and gradient system equipped with an anion exchange column, a 
Milton Roy Spectromonitor 3100 Variable wavelength Detector 
and a Perkin Elmer Sigma 15 Chromatography Data Station. The 
column was a 4.6 mm x 250 mm stainless steel column packed 
with SynChropak AXJ000, 6.5µ pore size (Synchrom Inc. 
Lafayette, IN). When a precolumn was used it contained the 
same packing material. 
The proteins were eluted from the column with a gradient 
buffer system (Kotake and Funae 1980). Mobile phase A 
contained 20 mM Tris (hydroxymethyl) aminomethane (Tris) acetate 
(pH 7.2), 0.2% Emulgen 911, and 20% (vol/vol) glycerol. 
Mobile phase B contained 0. 4 M sodium trifluoroacetate in 
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mobile phase A. Proteins were eluted with a 40 minute linear 
gradient from 100% mobile phase A to 0% mobile phase A, _100% 
mobile phase B. The elution of heme-containing protein was 
monitored by light absorption at 417nm. 
oexamethasone Induction of cytochrome P450s 
Virgin female, pregnant or lactating mice were treated by 
gavage with 300 mg/kg body weight/day of dexamethasone 
dissolved in corn oil (Watkins et al. 1989). The mice were 
treated in the morning for two days and killed by cervical 
dislocation two days after the last dose. Hepatic microsomes 
were prepared and solubilized for HPLC analysis of changes in 
the cytochrome P450 elution profile. The treatment schedule 
was planned so that pregnant mice were killed on day seventeen 
of gestation and lactating mice on day seventeen of lactation. 
Hormonal Induction of P450gest 
Virgin female mice at least six weeks old were housed 
three per cage with each treatment group in a separate cage. 
In the first phase five mice were treated with a combination 
of steroid and peptide hormones to induce hepatic microsomal 
P450gest (Nandi 1958). Progesterone, P-estradiol, and 
hydrocortisone were obtained from Sigma Chemical Co. St. 
Louis, Mo. Highly purified ovine prolactin (NIADDK-oPrl-19 
AFP-9221-A) and ovine growth hormone (NIADDK-oGH-15 AFP-7649-
C) were obtained from the National Hormone and Pituitary 
Program, National Institute of Diabetic and Digestive and 
Kidney Disorders. Prolactin ( 1 mg/mouse/day) and growth 
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hormone (1 mg/mouse/day) were suspended in normal saline at 1 
mg/0.2 ml. and given by subcutaneous injection in the-skin 
fold at the back of the neck. The animals received one 
treatment per day between 9:00 a.m. and 10:00 a.m. Treatment 
was continued for seventeen days. Hydrocortisone ( 62. 5 
µg/mouse/day), p-estradiol {l µg/mouse/day) and progesterone 
{1 µg/mouse/day) were dissolved in 0.2 ml sesame oil. 
Hormones were combined so that each mouse received no more 
than one aqueous and one sesame oil injection per day. 
steroids were administered for twelve days beginning on the 
same day as the protein hormones. Hydrocortisone was 
continued at 125 µg per day on treatment days thirteen through 
seventeen. All animals were killed by cervical dislocation 
twenty-four hours after the last injection. In the second 
phase, each hormone and each combination of two, three or four 
hormones was administered to a group of three mice. The same 
treatment schedule as was used in the combined treatment was 
maintained for each hormone. 
The effects of hormone treatments were compared by 
measuring the Area Under the Curve (AUC) for the HPLC elution 
peak of cytochrome P450gest. Differences between treatment 
groups were tested using the General Linear Models Procedure 
of the Statistical Analysis System (SAS Cary, NC) to calculate 
least square means, standard error of the mean and the 
probability of the difference. 
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purification of Cytochrome P450gest 
cytochrome P450gest was purified from hepatic microsomes 
prepared from 144 day seventeen gestation mice using HPLC 
detection to monitor the purification. The purification 
scheme was similar to the purification of other cytochrome 
P450s (Funae and Imaoka 1985, 1987). The microsomes were 
prepared as described for HPLC. Sodium chelate (10%) was 
added and the microsomal suspension was homogenized on ice. 
The microsomes were diluted with 0.1 M potassium phosphate 
buffer (pH 7.2) containing 20% glycerol, 1 mM EDTA and 0.5 mM 
OTT. An equal volume of 20% glycerol was added to reduce the 
concentration of potassium phosphate to 0.05 M, EDTA to 0.05 
mM and OTT to O. 25 mM. The final concentration of protein was 
5 mg/ml and of sodium cholate was O. 7%. The mixture was 
stirred on ice for 30 minutes before loading on an octylamino 
sepharose 4B column (5 cm x 15 cm.). The column had been 
washed with 0.1 M potassium phosphate (pH 7.2), 1 mM EOTA, 1 
mM OTT, 20% glycerol and 0.5% sodium chelate. The elution 
buffer was the same as the wash buffer except that the sodium 
chelate was reduced to 0.4% and Emulgen 911 was added to 0.2%. 
The elution of protein and Emulgen was monitored at 260 nm. 
The eluant (approximately 1000 ml) was concentrated to one 
tenth the original volume and diluted with an equal volume of 
0.02 M tris acetate (pH 7.5), 20% glycerol and dialyzed for 24 
hours against fifty volumes of 0.02 M tris acetate (pH 7.2) 
and 2 0% glycerol. The dialyzed sample was loaded onto a 
46 
preparative DEAE-5PW column (2.5 x 10 cm ToyoSoda Mfg. co., 
Tokyo, Japan) using an Elilex Laboratories Inc. Model E-120-s 
pump. The loading rate was 2 ml per minute. The protein 
1oaded column was transferred to the gradient pump system and 
the initial protein was eluted with 0.4% Emulgen 911 in 0.02 
M tris acetate (pH 7.5) and 20% glycerol. After the initial 
protein fraction had eluted a 180 minute gradient from o to 
20% gradient buffer (elution buffer plus 1 M sodium acetate) 
was started. Three fractions of protein were collected. The 
separation with DEAE-5PW was repeated using an analytical 
column (7.5 X 74 mm) with the same buffer and gradient system. 
The fractions were diluted two fold to reduce the salt 
concentration and the volume was reduced until the protein 
concentration was approximately 3 mg per ml. The final 
protein separation step used a hydroxyapatite column (KB-
column Koken Co. Tokyo, Japan) equipped with a 5 ml injection 
loop. The elution buffer contained 0.01 M sodium phosphate 
(pH 7.4) 0.4% Emulgen 911, 20% glycerol and sodium cholate. 
The gradient buffer contained O. 35 M sodium phosphate with the 
same concentrations of Emulgen 911, glycerol, and sodium 
cholate. The column was loaded and washed for 10 minutes with 
the elution buffer at a flow rate of 0.07 ml per minute. The 
gradient buffer was increased from 0% to 57% over forty 
minutes, then increased to 100% in five minutes. Emulgen 911 
was removed from the samples after diluting three fold with 
20% glycerol and concentrating to five ml. The column (0.7 x 
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5 cm) contained three ml of Hydroxylapatite {BioRad Melville, 
NY). Emulgen 911 was removed by washing the column with .0.01 
M sodium phosphate (pH 7.4) 20% glycerol, and 0.05% sodium 
chelate. Elution of Emulgen 911 was monitored at 280 nm. 
When the Emulgen was removed the buffer was changed to 0.35 M 
sodium phosphate (pH 7.4) in 20% glycerol and 0.05% sodium 
chelate and the elution of P450 was monitored at 417 nm. The 
buffer flow rate was 0.5 ml per minute. 
Testosterone Hydroxylation Assay 
Site and stereospecific hydroxylation of testosterone by 
microsomal protein or by purified protein was measured by Ors. 
Funae and Imaoka using their method ( Imaoka et al • 19 8 8) • The 
metabolites were separated by reverse phase HPLC using a 
methanol, water, acetonitrile solvent system with elution of 
the metabolites monitored by uv absorption at 254 nm (Imaoka 
et al. 1987; Funae and Imaoka 1987). Purified P450gest (30 
pmol) was reconstituted with NADPH dependent Cytochrome P-450 
reductase (0.3 units), NADPH (0.2 µmoles), and testosterone 
(0.5 µmole) with or without cytochrome b5 (30 pmol) with one 
of two possible lipid environments. The conventional lipid 
environment was 10 µg of dilauroylphosphatidylcholine (DLPC). 
The other lipid environment was a mixture of dioleoylphospha-
tidylcholine and phosphatidylserine (1:1) with 100 µg sodium 
chelate. The cytochrome b 5 and the NADPH dependent reductases 
were purified from mouse tissue when measuring mouse P-450 
activity and from rat when measuring rat P-450 activity. 
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Table 2. Purification Procedure for P450gest. Hepatic 
microsomes prepared from day seventeen gestation mice were 
used to purify P450gest using a combination of open column 
chromatography and preparative scale HPLC. Further details of 
the column packing material and the buffers are in the text. 
Table 2 
Purification Procedure for P450gest 
MICROSOMES 
Solubilized with 
sodium cholate 
OCTYLAMINO-SEPHAROSE 4B 
COLUMN 
0.2% Emulgen 911 
in phosphate, glycerol 
and cholate buffer 
ANION-EXCHANGE PREPARATIVE HPLC 
Column: DEAE-5PW (Toyo 
Soda) 2.15 x 15 cm 
Na-acetate gradient in 
acetate, glycerol, 
Emulgen 911 buffer 
ANALYTICAL HPLC 
Column: DEAE-5PW 
7.5 X 74 mm 
HYDROXYLAPATITE HPLC 
ANION-EXCHANGE 
I 
Column: KB Type S (Koken) 
6 X 100 mm 
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preparation of Polyelonal Antibodies to P450gest 
Polyclonal antibodies were raised in female New Zealand 
rabbits as described by Thomas et al. (1976). Control sera 
were obtained by bleeding the rabbits from the marginal ear 
vein before the protein injections were begun. Equal weights 
of cytochrome P450gestl and P450gest2 were combined and the 
proteins were prepared for injection by mixing the total 
volume of protein with an equal volume of Freunds complete 
adjuvant. Twenty-five micrograms of protein in a total volume 
of 50 µl were injected intradermally in a total of three sites 
into the shaved flank of the rabbits. Four weeks later the 
animals were given booster injections of 25 µg of protein 
suspended in an equal volume of Freund's incomplete adjuvant. 
seven days later the animals were bled from the marginal ear 
vein. The animals were given booster injections at four week 
intervals and bled one week later for a total of five times. 
Antibodies were prepared from serum after the blood had 
been allowed to clot at room temperature for one hour. The 
serum was removed from the clot by centrifugation and ammonium 
sulphate was added to give 50% saturation. The immunoglobulin 
precipitate was removed by centrifugation and washed by 
suspending the protein in 1.75 M ammonium sulphate and 
centrifuging. The wash procedure was repeated until the 
immunoglobulin precipitate was white. 
dissolved in 10 mM sodium phosphate 
This white pellet was 
(pH 7. 0) and dialyzed 
overnight against distilled deionized water. The dialysate 
51 
was centrifuged to remove lipoproteins and dialyzed overnight 
against 10 mM sodium phosphate buffer (pH 8.0). Albumin and 
plasminogen were removed from the dialysate with a column of 
CM Affi-gel Blue (Bio-Rad) using 3.9 ml of gel for each ml of 
rabbit serum. The column was washed and equilibrated with 
o. 01 M potassium phosphate, O .15 M sodium chloride buffer 
following the manufacturers recommendation. The 
immunoglobulin was eluted from the column with 0.01 M 
potassium acetate, O .15 M sodium chloride (pH 7. 25) and 
concentrated by addition of ammonium sulphate to 50% 
saturation and centrifugation. The pellet was resuspended in 
20 mM sodium acetate, 0.15 M sodium chloride (pH 7.0) buffer 
equal to one fifth the original volume of serum. 
Gel Electrophoresis and Western Blot 
Microsomal protein or purified protein was separated by 
polyacrylamide gel electrophoresis with sodium dodecyl sulfate 
denaturation (PAGE-SOS) in a Pharmacia Gel Electrophoresis GE 
2/4 LS apparatus using a 10% acrylamide separating gel and a 
3.5% stacking gel (Sambrook et al. 1989 pp 18.51-18.54). The 
running buffer contained 25 mM tris, 192 mM glycine and 0.1% 
sos. After electrophoresis, the protein was transferred to 
Nytran membrane (Schleicher and Schuell Keene, NH) in a Trans-
Blot Cell (Bio-Rad Laboratories Melville, NY) using 25 mM tris 
(pH 8.3) 192 mM glycine 20% methanol as the transfer buffer. 
Gels were equilibrated in the transfer buffer before loading 
into the Trans-Blot apparatus where electro-transfer was 
52 
carried out at 100 V for four hours (Towbin et al. 1979). 
The membrane was blocked with 5% nonfat dry milk in TTBS 
(tris buffered saline contains 20 mM tris, 500 mM sodium 
chloride pH 7.5 and 0.5% Tween-20) for two hours to overnight 
and washed with TTBS. Specific proteins were detected with a 
primary antibody diluted 1:1000 in TTBS with 1% nonfat dry 
milk followed by binding to horseradish peroxidase coupled 
goat antirabbit IgG (BioRad Laboratories Melville NY), diluted 
1:2000 in TTBS with 1% dry milk. The color was developed with 
3,3'diaminobenzidine tetrahydrochloride dissolved in methanol 
and added to TBS containing H2o2 as described by the supplier. 
The final concentration of H2o2 was 0.015%. The reaction was 
stopped by washing the membrane in water. 
Preparation of cDNA Expression Library 
The liver of a day six gestation mouse was used for the 
preparation of RNA to use in synthesizing a cDNA library. The 
mouse was killed by cervical dislocation and the liver was 
quickly removed, blotted, wrapped in tared aluminum foil, 
frozen in liquid nitrogen and stored at -70° c. Total RNA was 
isolated from this frozen liver by denaturing the protein with 
a GTC solution (6 M guanidinium thiocyanate, 5 mM sodium 
citrate and 0.5% sodium sarkosyl) using 5 ml of solution per 
gram of liver. The DNA was sheared by passing the solution 
through a 20 gauge needle several times and protein was 
removed by one extraction with an equal volume of 
phenol:chloroform (1:1). The lysate was loaded onto a cushion 
53 
of 6.1 M cesium trifluoroacetate (CsTFA, pH 7.5, density 1.53 
g/ml) and centrifuged overnight at 45000 rpm using a Beckman 
vso rotor. The upper layers of lysate and DNA were removed 
from the centrifuge tube, and the tube was rinsed above the 
csTFA with GTC solution. The tube was cut just below the 
level of the interface and the CsTFA decanted. The pellet was 
washed with ethanol and dried. The RNA pellet was dissolved 
in sterile water and made o. 2 M with NaCl before precipitating 
by the addition of sodium acetate to 0.3 Mand two volumes of 
ethanol and storing in dry ice for twenty minutes. After 
centrifuging at 4°C the pellet was washed once with 80% 
ethanol and dried. 
Poly (A) •RNA was prepared from the total RNA with an 
oligo(dT) cellulose Type 3 (Collaborative Research 
Incorporated, Bedford, MA) packed column which had been washed 
with 0.3 N NaOH followed by High Salt Buffer (50 mM Tris (pH 
7. 5) , 0. 2 M NaCl, 5 mM EDTA] . The total RNA pellet was 
dissolved in 8 ml of sterile diethylpyrocarbonate (DEPC) 
treated water, and heated to 65°C for two minutes. After 
cooling to room temperature two ml of 5X high salt buffer were 
added and the sample was applied to the oligo(dT) column. The 
column was washed with 20 ml of High Salt Buffer before 
eluting the Poly(A).RNA with 5 ml water. The eluate was 
collected in five fractions. RNA content of the total RNA 
before the oligo(dT) column and of each fraction was measured 
using the absorbance at 260nm and 280nm. Fractions one and 
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two, which contained the highest concentration of RNA, were 
combined and the RNA precipitated from 0.3 M sodium acetate 
with 2.5 volumes of ethanol. A 4 µg aliquot of the purified 
mRNA was diluted to 25 µl with sterile DEPC treated water and 
used for synthesis of double stranded cDNA using the cDNA 
synthesis System (GibcoBRL Gaithersburg, MD) following the 
protocol supplied with the kit. 
The first strand DNA was synthesized by the Moloney 
murine leukemia virus reverse transcriptase with a 32p dCTP 
included to permit monitoring the level of products during 
the synthesis of cDNA. Second strand DNA synthesis was 
carried out with E.coli DNA Polymerase I in the presence of 
RNase Has described in the cDNA Synthesis System Kit. After 
incubating at 16°C for two hours, the enzymes were denatured 
by heating at 70°C for ten minutes and the incubation mix was 
cooled on ice. The reaction (total volume 400 µl) was stopped 
with 40 µl of 0.25 M EDTA and 40 µl of 10% SOS followed by 
two extractions with an equal volume of phenol: chloroform 
(1:1). The cDNA was precipitated with two volumes of ethanol 
in the presence of 2 M ammonium acetate, placed on dry ice for 
20 minutes, and centrifuged in a micro centrifuge at 4°C for 
15 minutes. The supernatant was placed on dry ice for an 
additional 20 minutes and centrifuged as for the first 
precipitation. The two pellets were combined in TE buffer 
(total volume 50 µl) and the cDNA was reprecipitated from 2.0 
M ammonium acetate with two volumes of absolute ethanol. 
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After centrifugation in a microcentrifuge at 4°C for 20 
minutes the pellet was dried and resuspended in 31 µl water. 
The double stranded cDNA was given blunt ends with T4 DNA 
polymerase (New England BioLabs Beverly, MA) using the buffer 
supplied with the enzyme plus 10 mM OTT. After incubating at 
37°c for three minutes, 0.1 volume of 1 mM dNTPs was added and 
the incubation continued for ten minutes. The reaction was 
stopped with 60 µl NET (0.15 M NaCl, 0.1 mM EDTA, 20 mM Tris 
at pH 8) and 5 µl 10% sos, then extracted with an equal volume 
of phenol (100µ1). The phenol was back extracted one time 
with 100 µl of NET. The two aqueous phases were combined and 
extracted once with phenol: chloroform (1:1). The cDNA was 
precipitated from the aqueous phase with an equal volume of 4 
M ammonium acetate and two volume of absolute ethanol. After 
washing with 80% ethanol, the cDNA pellet was dried and 
dissolved in 60 µl water. 
Before addition of linkers containing EcoRI restriction 
sites internal EcoRI sites were protected by methylation. The 
methylation was catalyzed by EcoRI Methylase (New England 
BioLabs Beverly, MA) in the presence of 4% bovine serum 
albumin using s-adenosyl methionine as the source of methyl 
groups and the buffer supplied with the enzyme. After 
incubating at 3 7°C for twenty minutes, the reaction was 
stopped by adding 100 µl NET. The reaction mix was extracted 
with an equal volume of buffered phenol and the phenol was 
back extracted one time with 100 µl of NET. The cDNA was 
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precipitated with ethanol as described above, dried and 
dissolved in 20 µl of water. 
EcoRI linkers, 2.5 µl of phosphorylated oligiomers 
containing the EcoRI restriction site (Collaborative Research 
Incorporated Bedford, MA), were added to the methylated, blunt 
end cDNA using 400 units (1 µl) T4 DNA ligase (New England 
BioLabs Beverly, MA) and the ligase buffer supplied with the 
enzyme. The ligation reaction was allowed to proceed at 14°C 
overnight. 
The cDNA with EcoRI linkers was diluted with 170 µl 
water and digested with 50 Units EcoRI (Gibco-BRL 
Gaithersburg, MD) using the reaction buffer supplied with the 
enzyme. After incubating at 37°C for three hours, the 
reaction was stopped by the addition of 5 µl of 10% sos and 
extraction with 200 µl phenol:chloroform (1: 1). Excess 
linkers were removed with a 5 ml column of CL-4B Sepharose 
(Pharmacia LKB Biotechnology Piscataway, NJ) prepared and 
equilibrated with 0.4 M NaCl, 10 mM Tris (pH 7.5) and 1 mM 
EDTA as described by Klickstein and Neve (in Ausebel et al. 
eds. 1989 pp 5. 6. 2-5. 6. 8) . The column eluant was collected in 
five drop aliquots and monitored by counting 2 µls of each 
fraction. The first three eluant fractions contained the 
first peak of counts. These were pooled and extracted once 
with an equal volume of phenol:chloroform (1:1). 
The cDNA with linkers was ligated into lgtll 
dephosphorylated arms with T4 DNA ligase using 1 µg of lgtll 
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arms for 100 ng cDNA and incubating at 14°C overnight. The 
ligated DNA was packaged into phage heads using Gigapa~k II 
Gold Packaging Extract (Stratagene LaJolla, CA) following the 
suppliers protocol. The packaged lgtll were suspended in SM 
buffer (one liter of SM buffer contains 5.8 gm NaCl, 2.0 gm 
MgSO4 , 50 ml 1 M Tris-HCl and 5 ml 2% gelatin). 
screening cDNA Library for Expression of P450gest 
Fresh Yl090r- cells were prepared by overnight incubation 
in sterile LB Media (Sambrook et al. 1989 p A.l) with MgSO4 • 
sterile MgSO4 was added after autoclaving to give a l0mM 
solution. 
The overnight culture was transfected with lgtll phage 
using 15 µl of phage suspension in 1.5 ml of Yl090r- cells and 
incubating at 37°c for 20 minutes to allow the bacteriophage 
to adsorb to the cells. The cell suspension was aliquoted 
into twenty tubes, seven ml of 0.7% agarose (Electrophoresis 
Grade GibcoBRL Gaithersburg, MD) held at 50°C was added and 
the culture was poured onto a 140 mm LB agarose plate. The 
plates were incubated at 37°C until plaques were visible. A 
nitrocellulose disk saturated with 10 mM IPTG and dried was 
placed on each plate and the incubation was continued at the 
same temperature overnight. The filters were coded to permit 
orienting to each plate and washed with blocking solution for 
six hours. Blocking solution contained 2. 5% Casein Hammarsten 
(BDH Chemical Liverpool, England) in TBS [20 mM tris-HCl (pH 
7.5) and 500 mM NaCl]. The filters were placed in antibody 
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dilution solution (ABS is 0. 5% Casein in TBS) containing 
rabbit polyclonal anti-P450gest diluted 1:1000 and incubated 
at room temperature overnight. The filters were washed one 
time in ABS, one time with 0.1% sos and 0.5% Triton-X in the 
ABS and finally with ABS. The filters were incubated with 
alkaline phosphatase conjugated goat anti-rabbit IgG diluted 
1: 1000 in ABS for two hours and washed following the same 
protocol as above plus a final wash with TBS. Bound alkaline 
phosphatase was detected with 5-bromo-4-chlor-3-indoyl 
phosphate with nitroblue tetrazolium (Kirkegaard & Perry 
Laboratories Inc. Gaithersburg, MD) as described by the 
supplier. 
Preparation of Bacteriophage DNA 
The nitrocellulose filters were reoriented to the plates 
and bacteriophage plaques corresponding to spots detected by 
the P450gest antibody were placed in one ml SM buffer 
(Sambrook et al. 1989 p A.7). 
Plating cells were prepared by inoculating 50 ml of LB 
media containing 0.2% maltose with a single colony of Yl09or· 
cells and incubating at 37°C overnight. The cells were 
centrifuged for 10 minutes at 3000 x g and room temperature, 
then resuspended in one half volume of sterile 10 mM MgSO4 and 
stored at 4°C. The 1gtll bacteriophage suspension (50µ1) was 
used to transfect 0.3 ml of Yl09or· plating cells by 
incubating at 37°c for 15 minutes, then adding 15 ml of LB 
media containing 10 mM MgSO4 and incubating with shaking until 
iysis occurred, usually six to 
centrifuging at 2000 x g (3200rpm) 
eight hours. 
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After 
in a Beckman Accu-Spin 
centrifuge for 10 minutes at 4°C, the supernatant was decanted 
into a clean 50 ml tube and 10 ml of a 50% slurry of DE52 in 
TYM media was added, the tubes were taped into a rack and 
placed on a rotary shaker for ten minutes. One liter of TYM 
media contained 10 gm tryptone, 5 gm yeast extract, 5 gm NaCl, 
and 10 ml of 1 M MgSO4 • The DE52 (Whatman Hillsboro, OR) was 
treated with 0.lM HCl and neutralized with NaOH (pH 7.0) then 
washed twice with TYM before preparing the final suspension. 
After centrifuging as in the previous step, residual DE52 was 
removed by passing the supernatant through a small Econo-
Column (BioRad Laboratories Inc. Melville, NY) and collecting 
the supernatant in a 50 ml centrifuge tube. One tenth volume 
of 3M sodium acetate and two-thirds volume of isopropanol 
were added and the samples were stored at -20°C overnight. 
The DNA was pelleted by centrifuging at 2000 x g and 4°C for 
twenty minutes. The supernatant was removed by decanting and 
the pellet was suspended in 1 ml 80% ethanol and transferred 
to a 1.5 ml tube. After centrifuging in a micro-centrifuge, 
the pellet was dried, suspended 
extracted twice with phenol 
in 0.5 ml. TE buffer, 
and one time with 
chloroform:phenol (1:1) and the DNA was precipitated from 0.3 
M sodium acetate with two volumes of ethanol. After 
centrifuging, the DNA pellet was washed with 80% ethanol and 
air dried. 
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Ligation of cDNA Fragments into M13mp18 
The plasmid M13mpl8 RF {Boehringer Mannheim Indianapolis, 
IN) was prepared for ligation by digesting with EcoRI 
(GibcoBRL Gaithersburg, MD) using the buffer supplied with the 
enzyme. Complete digestion was verified by electrophoresis on 
a 1% agarose gel. The 5' phosphate ends were removed with 
alkaline phosphatase from calf intestine {Boehringer Mannheim 
Indianapolis, IN). After incubating at 37°C for two hours, 
the alkaline phosphatase was removed by extraction with 
chloroform:phenol {l: 1) and the DNA precipitated from the 
aqueous phase with sodium acetate and ethanol {Sambrook et al. 
1989 pp El0-El5). 
Bacteriophage containing cDNA that hybridized with rat 
CYP3Al was digested with EcoRI. Specific DNA fragments were 
separated by electrophoresis on a 1% agarose gel. Fragments 
longer than 200 base pairs were cut from the agarose gel and 
placed in a 0.9% agarose gel perpendicular to the electrical 
field. The DNA was trapped on DEAE paper {Schleicher & 
Schuell NA45) by electrophoresis and recovered from the DEAE 
paper by eluting into 1.0 M NaCL, 0.1 mM EDTA, 20 mM Tris {pH 
8) at 65° c following the suppliers protocol. The purified 
DNA was ligated into the prepared Ml3pUC18 by incubating 
overnight at 14°C with T4 Ligase {GIBCO BRL Gaithersburg, MD) 
using the buffer provided by the supplier. The ligated DNA 
was diluted five fold with TE buffer and used to transform 
DH5a Competent E. Coli {GIBCO BRL Gaithersburg, MD) following 
the protocol provided with the cells. 
preparation and Sequencing of Plasmid DNA 
61 
LB broth (5 ml) containing lµg/ml of ampicillin was 
inoculated with a single colony of transformed cells and 
incubated overnight at 37°C with shaking. Two 1.5 ml aliquots 
of the incubate were used for each DNA preparation. Plasmid 
DNA was prepared by alkaline lysis as described by Kraft et 
al. (1988). 
Dideoxy chain termination sequencing was carried out 
using the Sequenase Kit (United States Biochemical Cleveland, 
Ohio) with double stranded plasmid DNA denatured by treating 
with NaOH and neutralized as described in the kit. The primer 
supplied with the kit was used for sequencing in the forward 
direction. MlJ/pUC Reverse Sequencing Primer (GIBCO BRL 
Gaithersburg, MD) was used for sequencing in the reverse 
direction. Sequencing products were separated on a O. 4 mm gel 
that contained 6% acrylamide/bis acrylamide gel in 8. 3 M urea, 
89 mM Tris base, 89 mM boric acid and 2 mM EDTA at pH 8.0. 
Electrophoresis was completed with a Thermoplate Sequencer Gel 
Electrophoresis Unit (International Biotechnologies Inc. New 
Haven, CT) at 60 watts supplied by an EC600 power supply (E-C 
Apparatus corporation st. Petersburg, FL). 
Preparation of Probe DNA 
DH5a cells containing plasmid 1-3 were incubated in 500 
ml of LB media containing 50 µg per ml ampicillin in a two 
liter flask. The cells were incubated overnight at 37°C with 
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shaking. The cells were removed by centrifuging and the 
plasmid DNA isolated by alkaline lysis (Sambrook et al •. 1989 
PP 1.38-1.45). Plasmid DNA was purified by centrifuging in 
ethidium bromide (115 µg/ml and cesium chloride (1.2 gm/ml) 
for 20 hours in a Beckman V50 rotor at 45000 rpm using quick-
seal tubes (Beckman Instruments Arlington Heights, IL). The 
ethidium bromide was extracted with an equal volume of CsCl 
saturated isopropanol. The phases were separated by 
centrifuging at 2000 rpm in a benchtop centrifuge and the 
isopropanol extraction was repeated. The DNA solution was 
dialyzed against 10 mM tris Cl (pH 7.5), 10 mM EDTA containing 
o.5 M NaCl for two hours. The NaCl concentration was reduced 
to 0.1 Mand the dialysis continued overnight. Finally the 
DNA solution was dialyzed against water for one hour. The 
dialysate was transferred to a 50 ml plastic tube and the DNA 
was precipitated by the addition of 0.1 volume of 3 M Na 
acetate and 2. 5 volumes of absolute ethanol. The DNA was 
dissolved in 0.5 ml of NET and extracted once with an equal 
volume of phenol, twice with chloroform:phenol (1:1) and once 
with chloroform. The purified DNA was precipitated from 0.3 
M Na acetate with 2.5 volumes of ethanol, centrifuged and the 
pellet dissolved in sterile water and stored in aliquots. 
Labeling of DNA Probe with ~p 
Plasmid 1-3 was digested with EcoRI and the 1000 and 400 
bp cDNA segments were purified by agarose gel electrophoresis 
and trapping in DEAE paper as described above. 
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Each DNA segment was labeled with 32P using the Klenow 
fragment of DNA polymerase and the protocol accompanying the 
oligioLabeling Kit (Pharmacia LKB Biotechnology Inc. 
piscataway, NJ). Unincorporated label was removed with a 
select-D, G-25 Spin Column and Collection Tube ( 5 Prime➔J 
prime Inc., West Chester, PA) following the product protocol. 
The radioactivity of the labeled probe (1 µl) was measured to 
verify adequate labeling. 
capillary Transfer of DNA to Nylon Membrane 
EcoRI digests of bacteriophage or plasmid DNA were 
separated by agarose gel electrophoresis. The DNA fragments 
were denatured by soaking the gel in O. 25 M HCl for 15 
minutes, briefly rinsing it in water and soaking in 0.5 N 
NaOH, 0.5 N NaCl 10 minutes. The DNA was transferred to 
MagnaNylon (Micron Separations Inc. Westborough, MA) by 
capillary transfer as described by Sambrook et al. 1989 (pp 
9.34, 9.45-9.46) using the final gel soaking solution as 
transfer media. The transfer was continued overnight. The 
nylon membrane was washed by shaking slowly in 1 M tris (pH 
7.2), 0.5 M NaCl at room temperature for 20 minutes. After 
drying the membrane at room temperature, the DNA was 
crosslinked to the membrane using ultra violet light 
(Stratolinker, Stratagene LaJolle, CA) and washed in 0.lx SSC, 
0.5% sos (lx SSC contains 0.15 M NaCl and 15 mM sodium citrate 
at pH 7.0). 
64 
gybridization of DNA with Labeled Probe 
The membrane with crosslinked DNA was prehybridized in 6X 
ssc, 5X Denhardt's solution, 0.5% SOS with 50 µg/ml denatured 
salmon sperm DNA at 65° C for 30 minutes. Denhardt' s solution 
(SOX) contains 1% Ficoll, 1% polyvinylpyrrolidone and 1% 
bovine serum albumin. The membrane-bound cDNA was hybridized 
with labeled probe from plasmid 1-3 in the same buffer. 
Hybridization was continued overnight at 65°C (Sambrook et al. 
1989 pp 9.52-9.55). The filter was washed two times with 2X 
ssc, 0.5% sos at 65°c and one time with 3X SSC 0.5% sos. The 
first wash was for 45 minutes followed by two washes at room 
temperature. The filter was exposed to X-ray film (Kodak XAR, 
Rochester NY) for two hours. 
Preparation of Total RNA 
Total RNA was prepared by homogenizing frozen liver in 10 
ml per gram tissue of denaturing solution (4 M guanidinium 
isothio-cyanate; 25 mM sodium citrate, pH 7.0; 0.5% sarcosyl; 
and o. l M 2-mercaptoethanol) • The RNA was purified by 
sequential addition of O.l volume 2 M sodium acetate (pH 4.0), 
1 volume water saturated phenol and O. 2 volume chloroform with 
vigorous vortexing after each addition. The phases were 
separated by centrifuging at 10,000 x g at 4°C for 10 minutes. 
RNA was recovered from the aqueous phase by the addition of an 
equal volume of 2-propanol, storing at -20°c for one hour and 
centrifuging at 3,000 x g and 4°C for 10 minutes. The RNA 
pellet was vortexed vigorously in O. 2 volumes 4 M LiCl to 
remove glycogen. 
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After centrifuging at 3,000 x g for 10 
minutes the pellet was resuspended in denaturing solution and 
the RNA recovered by the addition of an equal volume of 2-
propanol and centrifuging as above. This pellet was 
resuspended in 75% ethanol to remove residual guanidinium and 
centrifuged. The final pellet was air dried and dissolved in 
sterile DEPC treated water. 
siotinylation of Plasmid 1-3 Probe 
one microgram of each EcoRI fragment from plasmid 1-3 was 
biotinylated following the protocol provided with the 
PolarPlex Random Primer Biotin Labeling Subkit (Millipore 
Corporation Bedford, MA) and the biotinylated probes were each 
dissolved in 20 µl of TE buffer. The effectiveness of the 
biotinylation reaction was determined by serial ten-fold 
dilutions for a total of six dilutions of the products. One 
microliter of each dilution was spotted onto Immobillin s 
membrane, air dried and crosslinked to the membrane with ultra 
violet light (Stratolinker, Stratogene LaJolla, CA). The 
biotinylated probe was detected using the PolarPlex Detection 
Kit (Millipore Corporation Bedford, MA) following the protocol 
supplied with the kit. The biotinylated DNA probe was bound 
to strepavidin followed by biotinylated alkaline phosphatase. 
The alkaline phosphatase reacted with Lumigen-PPD to release 
one phosphate group and a product that emits yellow-green 
light that can be detected by exposure to x-ray film. 
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Reverse Transcriptase-Polymerase Chain Reaction 
Total RNA prepared from a day 17 gestation mouse was.used 
as a template for preparing first strand cDNA using oligo(dT) 
as the primer and using RNaseH· Reverse Transcriptase 
following the manufacturers protocol (Gibco-BRL Superscript 
preamplification System). The first strand DNA was amplified 
with Taq DNA Polymerase (Cetus Perkin Elmer) as described in 
the manufacture's protocol. The forward primer was 
5'CUACUACUACUATTTGGCCCAGTGGGGATAATG3', the sequence from 
plasmid 1-3 that corresponds to Cyp3a-11 nucleotides 398 
through 418. The reverse primer was 3'GTAAGGGAGTTCCTCAAGA-
UACUACUACUAC5' from plasmid 17R10-l. This sequence corresponds 
to nucleotides 1589 through 1608 of Cyp3a-11. Amplification 
was carried out with 40 cycles of 30 seconds at 94°c, one 
minute at 50°C and two minutes at 72°C. Electrophoresis of an 
aliquot on a 1% agarose gel indicated that a product of 
approximately 1200 bp was produced. The remainder of the PCR 
product was transferred to a clean tube and purified with 
Magic PCR Prep DNA Purification Resin (Promega, Madison WI) 
following the suppliers protocol. 
The PCR products were cloned into the pAMP 1 vector using 
the CLONEAMP Kit (GIBCO BRL, Gaithersburg MD) following the 
manufacturers protocol. Briefly, the PCR products were 
treated with uracil DNA glycosylase to remove the uracils at 
the 5' end of each strand leaving a 3' single strand sequence 
that can be annealed to the complementary sequences in the 
pAMP· 
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The plasmids were used to transform Dh5a Competent 
cells as described above. 
Plasmid DNA was prepared by alkaline lysis and digested 
with Pst I and Hind III to remove the PCR product insert. The 
digest was separated on a 1% agarose gel, and the DNA 
fragments were transferred to Immobilin-s membrane (Millipore 
corp. Bedford MA) by capillary action using l0X SSC as the 
transfer buffer. The DNA was crosslinked to the membrane as 
described above and hybridized with biotinylated plasmid 1-3. 
RNA Electrophoresis and Northern Blotting 
Total RNA was fractionated by electrophoresis under 
denaturing conditions (Sambrook et al. 1989 pp 7. 43-7. 45) 
using a formaldehyde agarose gel prepared in lX gel running 
buffer. The gel MOPS running buffer ( SX) contains o .1 M 3-(N-
MorpholinoJ propanesulfonic acid, 40 mM sodium acetate and 5 mM 
EDTA (pH 8.0). RNA was denatured by heating to 65°c in lX 
MOPS running buffer, 1% formaldehyde and 50% formamide for 15 
minutes. After cooling on ice, one tenth volume of 
formaldehyde gel loading buffer was added. The gel loading 
buffer contained 50% glycerol, 1 mM EDTA (pH 8. O) , O. 25% 
bromophenol blue and 0.25% xylene cyanol FF. The sample was 
applied to an agarose gel in a DNA Subcell (BioRad). Two sets 
of RNA were loaded, one for ethidium bromide staining and one 
for Northern Blot. The electrophoresis was run at 75 volts 
(EC600 power supply) for approximately three hours. The gel 
was cut between the two sets of samples and one half was 
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stained with ethidium bromide (5 µg per ml in 0.1 M ammonium 
acetate). The second half was rinsed in DEPC treated water to 
remove the formaldehyde and transferred to Immobilin-S 
(Millipore) by capillary transfer using 20X SSC as the 
transfer buffer. Transfer was carried out overnight at 4°C. 
After transfer, the membrane was dried at ao0 c for 30 minutes 
and the RNA was crosslinked to the membrane by uv radiation 
(Stratagene Crosslinker). 
The membrane was prehybridized in 6X SSC, SX Denhardt's 
solution, 0.5% SOS with 100 µg/ml denatured, sheared salmon 
sperm DNA. The bound RNA was hybridized with the same 
solution containing 20 ng/ml biotinylated cDNA from phage 1. 
The hybridization was overnight at 65°c. The hybridized blot 
was washed two times at room temperature in 2X SSC, 0.1% sos 
and two time in lX SSC, 0.1% sos at 60°C. Hybridized 
biotinylated probe was detected with Lumigen-PPD as described 
above. 
Results 
cytochrome P450gest was first identified as a new peak in 
the HPLC profile of hepatic microsomes prepared from pregnant 
c57Bl/6J mice as compared to virgin females of the same 
strain. This peak was not induced by treatment with 3-methyl-
cholanthrene, phenobarbital or PCN (Lambert et al. 1987). 
Physiological Induction of P450gest 
The HPLC profiles for male mice and for postpartum female 
mice were determined to test the effects of other hormonal 
states on the HPLC profile. As shown in Figure 1, the level 
of P450gest in postpartum mice depended on both lactation 
state and length of lactation. At three days postpartum, 
P450gest was detectable but at a decreased level as compared 
to pregnant mice in both nonlactating and lactating mouse 
hepatic microsomes. At seventeen days postpartum, when milk 
production is high, lactating mouse microsomes contained more 
P450gest than was found in pregnant mice. Microsomes from 
nonlactating mice at seventeen days postpartum had P450gest 
levels similar to the level at three days postpartum. Both 
pregnancy and lactation appeared to alter the levels of other 
heme containing proteins that elute before 15 minutes with the 
constitutively expressed P450s. As shown in Figure 2, the 
peak for P450gest was not apparent in microsomes from male 
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Figure 1. HPLC elution profiles for Postpartum Mice. 
solubilized hepatic microsomes from lactating and nonlactating 
postpartum mice (0.5 mg protein) were eluted with a 40 minute 
gradient of Oto 0.4 M NaTFA in a phosphate glycerol buffer as 
described in the methods section. Detection of heme 
containing proteins was by absorption at 417 nm (shown on the 
y axis). Elution time is shown on the x axis. Lactating dams 
were housed with their pups. Pups were removed from 
nonlactating dams on postpartum day 1. 
peak that elutes between 16 and 17 
P450gest is the solid 
minutes as shown by 
comparing the HPLC profiles for virgin and gestation day 17 
mice. 
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Figure 2. HPLC Elution Profiles for Virgin, Pregnant and Male 
Mice. Solubilized hepatic microsomes were prepared from virgin 
female, day 17 gestation and male mice. Elution and detection 
were carried out as described under Figure 1. For this 
column, P450gest elutes between 20 and 21 minutes. 
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mice. 
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Two other peaks, one eluting between 14.5 and 15.5 
minutes and the other eluting between 17.5 and 18.5 minutes, 
were increased in male as compared to virgin or pregnant mice. 
Induction of P450gest by Hormone Treatment 
Phenobarbital, 3-methylcholanthrene and PCN which 
represent three classes of exogenous inducers of cytochrome 
P450 did not alter the level of the P450gest peak (Lambert et 
al. 1987). Since there are examples of specific cytochrome 
P450s that are not induced by the antiglucocorticoid PCN but 
are induced by glucocorticoids, the effect of dex on the HPLC 
profile of virgin female and pregnant mice was tested. Dex did 
not induce P450gest in virgin or pregnant mice (see Figure 3). 
Another peak eluting at between 17 and 19 minutes was 
increased by dex in virgin and pregnant mice. 
Both pregnancy and lactation, which did increase 
P450gest, alter the circulating level of several hormones 
including some that are known to have a role in regulating the 
level of other P450s, such as growth hormone, progesterone and 
glucocorticoids. Initial studies of possible hormonal 
induction of P450gest used three day treatments with 
progesterone, estradiol or prolactin. These short term 
treatments did not alter the P450 profile of mouse hepatic 
microsomes as measured by HPLC. Therefore the effect of 
treatment with a combination of hormones on the HPLC profile 
was tested in collaboration with Dr. Jose Gonzalez. The 
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Figure 3. HPLC Elution Profiles for Dexamethasone Treated 
Mice. The area under the curve for P450gest was not 
detectable in the dex treated virgin mice. For the untreated 
and treated pregnant mice the areas under the curve for 
P450gest were 0.65 and 0.40 units, respectively. Dex 
increased the peak at 17 minutes from 0.55 to 4.60 area units 
in pregnant mice. For the treated virgin mouse, the peak area 
at 18 minutes was 6.0. 
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combination of hormones and the time schedule used is known to 
induce mammary gland development equivalent to late lactation. 
(Nandi 1958). The combination of three steroid hormones, p-
estradiol, progesterone and hydrocortisone and two peptide 
hormones, growth hormone and prolactin, administered for 
seventeen days induced P450gest when compared to virgin 
untreated or vehicle treated female mice. The areas under the 
curve for the peaks eluting at the same time as P450gest for 
the three groups of mice are given in Table 3. Mice treated 
with both injection vehicles, sesame oil and saline, did not 
have demonstrable changes in the P450gest peak. Treatment 
with the hormone combination induced P450gest as compared to 
the vehicle treated virgin mice (p=0.02) but the degree of 
induction was less than for gestation day seventeen mice 
(p=0.05). 
Once the capacity of the combination of hormones to 
induce P450gest was established, the effect of long term 
treatment with individual hormones administered according to 
the same protocol as in the combined treatment was studied. 
The only hormone that induced P450gest when administered alone 
was prolactin. As shown in Table 4, the AUC for hepatic 
P450gest in mice treated with prolactin was increased as 
compared to virgin mice (p=0.009), although the protein level 
was less than occurs on day seventeen of gestation (p=0.003). 
As shown in Table 4 neither hydrocortisone or growth hormone 
induced P450gest. When these two hormones were combined in 
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Table 3. Induction of P450gest with Combined Hormones. The 
area under the curve (AUC) and the standard deviation (SD)" for 
the P450gest peak in HPLC elution profiles of hepatic 
microsomes prepared from female mice are given. The 
polyhormonal treatment consisted of seventeen daily 
subcutaneous injections of growth hormone and prolactin in 
saline, seventeen daily injections of hydrocortisone in sesame 
oil and twelve daily injections of estradiol and progesterone 
in sesame oil. The treatments started on the same day. The 
vehicle control mice received daily injections of normal 
saline and sesame oil. The pregnant mice received no 
treatment. The AUC for P450gest was measured using a Perkin 
Elmer Sigma 15 Chromatography Data Station. 
Table 4. Induction of P450gest with Single Hormones. The 
effect of treatment with individual hormones on the level of 
P450gest in hepatic microsomes was determined using the HPLC 
profile to monitor changes. Growth hormone, prolactin or 
hydrocortisone were administered for seventeen days; estradiol 
or progesterone were administered for twelve days as described 
for the polyhormonal treatment. The mice were killed the 
morning after the last treatment. The values for the AUC of 
the P450gest peak for vehicle injected virgin and gestation 
day seventeen mice are given in Table 3. 
Table 3 
Induction of P450gest with Combined Hormones 
Treatment P450gest 
AUC±SD 
virgin 0.1±0.2 
pregnant (d17) 4.4±2.5 
polyhormonal 1.6±1.1 
Table 4 
p vs 
virgin 
0.0001 
0.02 
Induction of P450gest with single hormones 
Hormone P450gest p VS p vs 
AUC±SD virgin pregnant 
prolactin 2.1±1.5 0.009 0.003 
growth hormone o.o 0.9 0.0001 
estradiol 0.7±0.3 0.4 0.0001 
hydrocortisone 0.5±0.8 0.6 0.0001 
progesterone 0.6±0.5 0.5 0.0001 
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the seventeen day treatment (Table 5) hepatic microsomal 
p450gest was increased as compared to the level found in 
virgin mice (p=0.0001) and did not differ from the level that 
occurs at day seventeen of gestation (p=0.2). 
In each case in which another steroid was added to the 
hydrocortisone and growth hormone treatment, the steroid did 
not alter the level of induction. Even when both progesterone 
and ,B-estradiol were added to the hydrocortisone, growth 
hormone treatment, there was no further induction of P450gest 
(p=O. 07) • 
Although either growth hormone combined with 
hydrocortisone or prolactin alone induced P450gest when the 
three hormones were administered together P450gest was not 
induced above the level in virgin mouse hepatic microsomes 
(p=0.06). This apparent interference between prolactin and 
growth hormone occurred in all treatments where prolactin was 
added to a regime that included growth hormone and 
hydrocortisone ( see Table 5) . Hydrocortisone had no effect on 
induction by prolactin or by any combination that included 
prolactin but did not include growth hormone (data not shown). 
Purification ot P450gest 
In order to further characterize the protein, cytochrome 
P450gest was purified from the liver of retired breeder female 
mice using octylamino sepharose in an open column and an 
analytical anion exchange column. This yielded a ten fold 
purification of a very small amount of P450gest. To obtain a 
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Table s. Induction of P450gest with Growth Hormone, 
Hydrocortisone and Prolactin. The AUC of P450gest in the HPLC 
profile is given for hepatic microsomes prepared from virgin 
female mice treated with combinations of hormones. G, growth 
hormone; c, hydrocortisone; Pl, prolactin; E, estradiol; Pr, 
progesterone. The treatment schedule for each hormone was as 
described for the polyhormonal treatment. The AUCs for the 
P450gest peak for virgin and pregnant mice are given in Table 
3. P vs G+C compares the AUC for treatment with a combination 
of three or more hormones with the AUC for treatment with 
hydrocortisone and growth hormone. P vs -Pl compares the AUC 
for a combination of hormones that includes prolactin with the 
same combination but without prolactin. The polyhormonal 
group in Table 3 is the same as the G+C+Pr+E+Pl group in Table 
5. For the polyhormonal group n=S, for all other study groups 
n=J. 
82 
Table 5 
Induction of P450gest with Growth Hormone, 
Hydrocortisone and Prolactin 
Hormone P450gest p vs p vs p VS p vs 
AUC±SD virgin preg G + C - Pl 
G+C 3.4±2.4 0.0001 0.2 
G+C+Pl 1.5±1.0 0.06 0.0003 0.04 
G+C+E 3. 7±1. 1 0.0001 0.4 0.8 
G+C+E+Pl 1.6±0.5 0.04 0.0004 0.02 
G+C+Pr 3. 3±1. 7 0.0001 0.2 0.9 
G+C+Pr+Pl 0.8±0.4 0.3 0.0001 0.007 
G+C+E+Pr 5.1±1. 8 0.0001 0.4 0.07 
G+C+Pr+E+Pl 1.6±1.1 0.02 0.0001 0.0001 
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1arger amount and higher purification, hepatic microsome 
prepared from 144 day seventeen gestation mice were used _for 
octyl aminosepharose open column and DEAE preparative scale 
HPLC as described in the methods section. This was done by 
or. Lambert in the laboratory of Or. Funae. The purification 
was monitored by the HPLC elution profile. P45Ogest separated 
as a single peak through all purification steps until the 
final preparative HPLC hydroxylapatite column. At that point 
there were two distinct peaks with the area of the second peak 
about one half that of the first peak (Figure 4) . These 
proteins were designated P45Ogestl and gest2 in the order of 
elution. As shown in Table 6, the specific content of P45O 
increased from O.53 nmole P45O/mg protein in the microsomes to 
14 nmole P45O/mg protein in the purified P45Os for a 27 fold 
purification. 
N-terminal Amino Acid Sequence of p450gest 
The N-terminal amino acid sequence was determined by Dr. 
Alan Smith at the University of California, Davis. As shown 
in Table 7, in the first twenty-seven amino acids, P45Ogestl 
and P45Ogest2 differed only at the second residue. P45Ogest2 
contained asparagine where P45Ogestl contained praline. 
When the amino terminal sequences of P45Ogestl and gest2 
were compared to other mouse Cytochrome P45O sequences, also 
shown in Table 7, the only P45Os that had substantial sequence 
identity with the pregnancy induced proteins were two P45O 
family 3 proteins isolated from dex treated male mice. 
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Figure 4. HPLC Elution Profile for Purified P450gest. The 
final step in the purification of P450gest was elution of the 
protein from a Hydroxylapatite column with a 40 minute 
gradient from 0.01 to 0.20 M sodium phosphate. Elution of the 
protein (dotted line) was monitored at 288nm and the elution 
of heme-containing P450 (solid line) was monitored at 417 nm. 
Elution time is given on the x axis and light absorption is 
on they axis. 
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Figure 4. HPLC Elution Profile for Purified P450gest. 
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Table 6. Purification of P450gest. P450gest was purified from 
hepatic microsomes prepared from day 17 gestation mice. The 
AH-Sepharose 4B step used an open column, the DEAE-SPW and 
Hydroxylapatite steps used HPLC columns. Buffers for each 
step are described in the methods section. Only fraction 3 
from the DEAE-SPW column contained P450gest. 
Purification 
step 
Microsomes 
AH-Sepharose 
DEAE-5PW 
fraction 1 
fraction 2 
fraction 3 
Table 6 
Purification of P450gest 
Total Cytochrome P450 
Protein total content recovery 
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1mgl __ (__ n ___ m __ o~l ... )__.( ..... n __ m-o .... l_./ __ m..._g.._} _ ( %__,_) ____ _ 
4520 2380 0.53 
4B 1000 42 
95 148 1.56 6.2 
88 198 2.25 8.3 
138 119 0.86 5.0 
Hydroxylapatite 
P450gestl 1.4 15.4 14.1 0.8 
P450gest2 1.52 7.6 14.6 0.3 
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Table 7. N-Terminal Amino Acid Sequences of P450gestl and 
gest2. The sequences for the two P450gest proteins were 
compared to other mouse cytochrome P450 sequences. The amino 
acid sequences are from the following sources: CYP3All, 
Yanigimoto et al. 1992; 3Al3, GenBank Accession Number X63023; 
lAl and 1A2, Kimura et al. 1984; 2A4 and 2A5, Lindberg et al. 
1989; 2B9 and 2Bl0, Noshiri et al. 1988; 209 and 2010, Wong et 
al. 1989a; 2El, Voliva and Paigen 1991, Freeman et al. 1992; 
2F2, Ritter et al. 1991; 17, Youngblood et al. 1991; 19, 
Terashima et al. 1991; 21, Chaplin et al. 1986. 
Table 7 
N-Terminal Amino Acid Sequences of P450gestl and P450gest2 
P450gestl 
P450gest2 
3All 
3Al3 
lAl 
1A2 
2A4 
2B9 
2Bl0 
2D9 
2D10 
2D11 
2El 
2F2 
17 
19 
21 
M P L F S A L S L D T W V L L A I I L V T S Y R Y G H 
N 
D V 
D I P 
P S M Y 
A F S Q 
L T S G 
D P S V 
E P S V 
E LT 
E LT 
E L T 
AV LG 
D G V 
WE L V 
F E M 
L PG 
E S LL T 
NF ME M TS LL L T 
G P A F V S A T E L L A T V F C R F 
Y I A P E L T A I F C L V F W M V 
L VAAVAF SLVLVLM VWKQY 
L L A V L L S F L L R G H A K I 
L L A L L G F L L L A R G H P K S R 
G T D W P V A I F T V F I L L V D L T 
G A G W S V A I F T V F I L L V D L M 
G A G W S V A I F T V F I L L V D L M 
I T V A L V W I A T L L S I W K Q I Y 
T A I L L L L A V I S L S L T F S S R G K 
G L L L I L A Y F F W P K S K T P N A K E 
L N P M Q Y N V T I M V P E T V T V S A M P 
L L L L L L A G T R W G Q W R L R K 
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cYPJAll and P450gest differ at seven of the twenty-seven amino 
acids for a 70% identity while CYP3Al3 and P450gest differ at 
fourteen amino acids for a 48% identity. This suggests that 
P450gest is in family CYP3. Table 8 gives the amino terminal 
sequences of all reported CYP3A proteins. Table 9 lists the 
calculated per cent identity between the reported CYP3 
sequences and P450gestl or gest2. Several of the reported 
CYP3 sequences were greater than 55% homologous with the two 
pregnancy induced mouse protein. The primate sequences and 
one of the two previously reported mouse sequences had 44 to 
48 per cent identity with P450gest. 
P450gest Metabolism of Testosterone 
Different cytochrome P450s can metabolize testosterone at 
different specific carbons with the hydroxyl group forming on 
either the a or the~ face. The data from Ors. Funae and 
Imaoka indicate that the most active site for testosterone 
metabolism by microsomes from either pregnant or virgin female 
mice is at the 6~ position with low but detectable activity at 
the 2~ and 15a sites (Table 10). This is the same as the 
testosterone metabolite profile for rat CYP3A proteins 
(Halvorson et al. 1990). Reconstituted purified P450gest had 
higher 6~ hydroxylation activity than at any other location, 
although there was also measurable activity for hydroxylation 
at the 2~ position -(Table 11) . There was no detectable 
testosterone hydroxylase activity at any other location. 
Activity of the purified P450 was strongly dependent on 
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Table 8. N-Terminal Amino Acid Sequences of CYP3As. The 
sequences for P450gest were compared to CYP3A sequences from 
other species. The amino acid sequences are from the 
following sources: CYP3Al (rat) Gonzalez et al. 1985; CYP3A2 
(rat) Gonzalez et al. 1986b; P-4506,,_ 2 and P-4506,,_4 (rat) Nagata 
et al. 1990; CYP3A3 (human) Watkins et al. 1985, Molowa et al. 
1986; CYP3A4 (human) Beaune et al. 1986, Bork et al. 1989, 
Gonzalez et al. 1988; CYP3A5 (human) Aoyama et al. 1989, 
Schuetz et al. 1989; CYP3A7 (human) Komori et al. 1989, Kitada 
et al. 1987; CYP3A6 (rabbit) Dalet et al. 1988; CYP3A8 
(monkey) Ohta et al. 1989, Komori et al. 1992; CYP3Al0 
(hamster) Teixeira and Gil 1991; CYP3All (mouse) Yanigimoto et 
al. 1992; and CYP3Al2 (dog) Ciaccio et al. 1991; CYP3Al3, 
GenBank Accession Number X63023. 
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Table 8 
Amino Terminal Sequences of CYP3As 
P450gestl M p L F s A L s LDT WV L L A I I L VT s y Ry G H 
P450gest2 N 
3All D V E s LL T 
3Al3 D I p N F M E M T s LL L T 
3Al D L T E V V LL G F 
3A2 D L T E V LL L T 
6/3-2 E I I p N I E T S M L F I T 
6/3-4 D L T E V V LL G F T 
3A3 A I p D AME L V S LL L T 
3A4 A I p D AME L V S LL L T 
3A5 D I p N AVE L V S LL L T 
3A7 D I p N AVE L V S I LL L T 
3A8 D I p D AVE L VT LL L T 
3A6 D I F S - - L E A S LL L T 
3Al2 D I p s F T E s LL T 
3Al0 E I p N I E I s L I I T 
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Table 9. Comparison of P450gest and other CYP3As. The N-
terminal amino acid sequence for P450gestl was compared with 
the comparable sequences from other CYP3A proteins. 
References for each protein are given in the Table 8 legend. 
The per cent identity between the N-terminal amino acid 
sequences of P450gestl and gest2 with the previously reported 
CYP3A proteins are equal to each other. 
Table 9 
comparison of P450gest and other CYP3As. 
mouse rat human monky rabt dog hmst 
3All 3Al3 3Al 3A2 3A3 3A4 3A5 3A7 3A8 3A6 3Al2 3Al0 
3All 100 
3Al3 70 100 
3Al 70 52 100 
3A2 81 59 85 100 
3A3 70 78 59 63 100 
3A4 67 78 56 63 85 100 
3A5 70 81 56 74 93 96 100 
3A7 70 78 56 63 100 85 89 100 
3A8 70 74 63 81 89 89 93 93 100 
3A6 76 80 64 63 76 76 80 76 76 100 
3Al2 78 85 56 56 78 81 81 78 78 84 100 
3Al0 74 74 59 63 70 74 74 74 70 80 74 100 
GEST 74 48 63 67 48 48 48 44 48 52 59 56 
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the reconstitution system. When enzyme activity was 
reconstituted by suspending purified P450gest and mouse NADPH 
dependent P450 reductase in dilauroylphosphatidylcholine there 
was no detectable activity at the 2~ position and low activity 
at the 6~ position. The presence of cytochrome b5 increased 
hydroxylation activity six fold for both P450gestl and gest2. 
Reconstitution with a 1:1 mixture of lecithin and 
phosphatidylserine in a system that included cytochrome b5 
doubled the rate of testosterone hydroxylation activity for 
both P450gestl and gest2. Each of these changes has a similar 
effect on the activity of rat CYP3A although cytochrome b 5 
with dilauroylphosphatidylcholine increased rat CYP3A activity 
only two fold as compared to the five fold increase in 
activity for the mouse proteins. 
Preparation and Verification of Anti-P450gest Antibodies 
In preparation for the isolation of bacteriophage that 
express P450gest to use in the determination of the cDNA 
sequence, Dr. Lambert and Cecilia Doyle raised polyclonal 
antibodies to P450gest in rabbits and tested the purified 
antibodies for specificity to P450gestl and gest2. Hepatic 
microsomes were prepared and the protein content was measured 
as for HPLC. For SOS-PAGE electrophoresis, each well was 
loaded with 5 µg of microsomal protein except well 12 which 
contained 2. 5 µg of P450gest. Microsomes from untreated male, 
virgin female mice, pregnant mice and from treated virgin mice 
were separated by SOS-PAGE, and transferred to nylon membrane 
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Table 10. Hepatic Microsomal Testosterone Hydroxylase 
Activity. Hepatic microsome were prepared from virgin and 
pregnant mice. Testosterone metabolites were separated by 
reverse phase HPLC using a methanol :water: acetonitrile solvent 
system with elution of the metabolites monitored at 254nm. 
The metabolites were identified by comparing the elution times 
with the elution time for known metabolites. 
Position 
Microsome 
source 
virgin 
pregnant 
Table 10 
Hepatic Microsomal Testosterone Hydroxylase Activity 
2a 
<0.01 
<0.01 
Testosterone Hydroxylase Activity 
(nmol/min/mg of microsomal protein) 
2{1_ 6a 6{1_ 7a 15a 16a 
0.19 0.47 1.73 0.35 0.20 0.20 
0.45 0.26 2.40 0.70 0.52 0.15 
16{1_ 
0.17 
0.26 
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Table 11. P450gest Testosterone Hydroxylase Activity. Purified 
Mouse P450gestl and gest2 and Rat CYP3A were reconstituted 
with NADPH-dependent cytochrome P-450 reductase and lipid with 
or without cytochrome b 5 (b5) as described in the methods. 
DLPC designates reconstitution with dilauroylphosphatidyl-
choline as the lipid. Mix designates reconstitution with 
lecithin, phosphatidyl serine and sodium chelate. 
Table 11 
P450gest Testosterone Hydroxylase Activity 
Testosterone Hydroxylase Activity 
(nmol/min/nmol P450) 
Position 28 68 
Cytochrome 
P-450 Lipid 
P450gestl DLPC (-b5 ) <0.2 1.01 
DLPC (+b5 ) 1. 30 5.79 
Mix (+b5 ) 2.98 12.1 
P450gest2 DLPC (-b5 ) <0.2 0.60 
DLPC(+b5 ) 0.67 3.42 
Mix (+b5 ) 1. 57 7.01 
CYP3A (rat) DLPC (-b5 ) <0.2 0.32 
DLPC (+b5 ) <0.2 0.65 
Mix (+b5 ) 2.11 13.9 
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by Western Blotting. 
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Rabbit anti-P450gest polyclonal 
antibodies recognized a single band at 51000 daltons (Figure 
s). This is the published size for P450gest (Lambert et al. 
1987). The antibody detected protein was apparently present 
at a higher level in pregnant (Lane 7) as compared to 
nonpregnant (Lane 1) or male mice (Lane 3) and was induced in 
the polyhormonal treated mice, lane 2, but not in mice treated 
with sesame oil and saline (lane 8). Neither phenobarbital, 
a CYP2A inducer or 3-methylcholanthrene, a CYPlA inducer, 
increased the level of P450gest (Figure 5, lanes 9 and 10). 
This agrees with previously reported HPLC data (Lambert et al. 
1987). Mice that had completed several pregnancies (retired 
breeders) had elevated levels of P450gest whether they were 
pregnant or nonpregnant (lanes 4 and 5). 
Sequencing cDNA from Pregnant Mouse Liver Library 
The cDNA library prepared from a day six gestation mouse 
was screened for expression of protein immunologically related 
to P450gest using the polyclonal antibodies raised in rabbits. 
When approximately 100,000 bacteriophage lgtll colonies were 
screened, eleven plaques were identified that expressed 
protein recognized by the rabbit anti-P450gest polyclonal 
antibodies. These bacteriophage were grown in small scale 
culture, digested with EcoRI and the DNA segments were 
separated by electrophoresis in 1% agarose. EcoRI restriction 
enzyme digests were separated by agarose gel electrophoresis, 
blotted to nitrocellulose and hybridized with human CYP3A4 DNA 
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Figure 5. Polyclonal Antibody to Cytochrome P450gest. Hepatic 
microsomes prepared from CS7BL/6J mice were separated by PAGE-
sos electrophoreses and transferred to nylon membrane by 
electro-blot. All microsomes were from female mice except 
lane 3 (untreated male). Nonspecific binding sites on the 
membrane were blocked with nonfat dry milk then hybridized 
with rabbit polyclonal anti-P450gest. Hybridized antibody was 
detected with mouse anti-rabbit IgG. Microsomal protein 
samples are: Lane 1, virgin female; Lane 2, polyhormonal 
treated virgin; Lane 3, untreated male; Lane 4, nonpregnant 
retired breeder: Lanes, pregnant retired breeder; Lanes 6 and 
14, standards: Lane 7, day 17 pregnant; Lane 8, vehicle 
treated virgin; Lane 9, phenobarbital treated virgin; Lane 10, 
3-methylcholanthrene treated virgin, Lane 11 and 13, blank; 
Lane 12 P450gest. Each lane contains 5µ.g of microsomal 
protein except Lane 12 which contains 2.5µ.g of P450gest. 
MOL WT. 
STD. (KDAL.) 
110 
84 
47 
33 
24 
16 
1 02 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Figure 5. Polyclonal Antibody to Cytochrome P450gest. 
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(Figure 6). Four of these, bacteriophage 1, 4, 10 and 12, had 
unique EcoRI restriction patterns. The cDNA inserts isolated 
from the phage were ligated into plasmids which were used to 
transform competent DH5a E. coli. The plasmid DNA was 
prepared and digested with EcoRI and the DNA fragments were 
separated by electrophoresis, transferred to nitrocellulose 
and hybridized with rat PCN2 cDNA to verify insertion of a 
CYP3A sequence. DNA was prepared from three to six plasmids 
from each of the bacteriophage 1, 4, 10, and 12, and the 
inserts were sequenced by dideoxy chain termination using both 
forward and reverse primers. 
The clones contained cDNA sequences that were greater 
than 80% identical to mouse CYP3All but only 60 to 70% 
identical to CYP3Al3. The sequences were not full length and 
were all at the 3' end of the mouse genes (see Figure 7). One 
sequence from phage 1 was closest to the 5' end with 97% 
sequence identity with nucleotides 391 through 547 of CYP3All 
and 74% identity with nucleotides 400 through 554 of CYP3Al3. 
Another sequence from phage 1 had 98% sequence identity with 
CYP3All positions 1116 through 1297 and 80% identity with 
CYP3A13 positions 1164 through 1297. These two sequences were 
obtained from different plasmids obtained by subcloning cDNA 
from phage 1. 
Plasmids prepared from phage 4 and 12 had short inserts 
of less than 150 base pairs. The insert in plasmid 4-2 had 
78% sequence identity with CYP3All nucleotides 1221 through 
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Figure 6. EcoRI digests of cDNA Detected by Antibodies to 
Expressed P450gest. The DNA from bacteriophage that expressed 
P450gest related proteins was digested with EcoRI and the cDNA 
fragments were separated on a 1% agarose gel, transferred to 
nitrocellulose and hybridized with a cDNA probe for rat CYP3A2 
Gonzalez et al. 1986b). 
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Figure 6. EcoRI digests of cDNA Detected by 
Antibodies to Expressed P450gest. 
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Figure 7. Map of Mouse Cyp3a Sequences. Bacteriophage lgtll 
that expressed protein related to P450gest were detected with 
antibodies to P450gest. The sequences of cDNA fragments 
isolated from the pregnant mouse library were compared with 
the previously published mouse sequences, CYP3All and 3Al3. 
The start site (ATG), EcoRI restriction sites (E), and the 
termination site (TGA) are give for mouse CYP3All and 3Al3 and 
for the new sequences. The relative location for sequences 
from phage 1, 4, 10, and 12 are given using the nucleotide 
numbers for CYP3Al3. The line length is proportional to the 
length of sequence for each cDNA. The total sequence length 
for CYP3All is 1690 nucleotides and for CYP3Al3 is 1881 
nucleotides. 
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3o-11 
ATG E E E TGA 
TT T T T 
3o-13 ATG E E TGA ,,. .. ,,. .. 
p1-3 
p4-2 E E ~ 
p10-5 TGA E .,,. ,,. 
p12 
Figure 7. Map of Mouse cyp3a Sequences. 
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l319, 65% identity with CYP3Al3 and 60 to 68% identity with 
the rat sequences CYP3Al and CYP3A2. Plasmids derived from 
phage 12 had 90 and 75% sequence identity with CYP3All and 
cYP3A13, respectively over the 122 base pair region 
corresponding to nucleotides 1327 through 1450 of CYP3All. 
The longest sequence obtained from a bacteriophage 
identified by the expression of protein detected by polyclonal 
antibodies to P450gest was from phage 10. This sequence, from 
plasmid 10-5, is given in Table 12 with the differences in 
CYP3All and CYP3Al3 shown above and below the new sequence, 
respectively. The sequence for plasmid 10-5 had 94% sequence 
identity with CYP3All positions 1335 through 1690 but plasmid 
10-5 had an additional 94 nucleotides after the end of the 
published sequence for CYP3All at position 1690. The identity 
between plasmid 10-5 and CYP3Al3 positions 1341 through 1597 
was 77%. The TGA stop signal for CYP3Al3 is at positions 1593 
through 1597. When the complete plasmid 10-5 sequence was 
compared to CYP3A13 positions 1341 through 1806 the sequence 
identity decreased to 62%. 
Because only the N-terminal amino acid sequence was known 
none of the sequences could be identified as P450gestl or 
gest2. Therefore the pregnant mouse liver cDNA library was 
rescreened with a rat CYP3A cDNA using approximately 200,000 
lgtll bacteriophage colonies. The colonies were transferred 
to nitrocellulose disks and hybridized with P450PCN2 cDNA, a 
rat CYP3A (Gonzalez et al. 1986). Twenty colonies (lR through 
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Table 12. cDNA Sequence Derived from Phage 10-5. The cDNA 
sequence derived from phage 10-5 from the pregnant mouse liver 
library was compared with Mouse CYP3All and 3A13 Sequences. 
There was 93.5% identity between the first 357 nucleotides of 
10-5 and nucleotides 1335 through 1690 of CYP3All, the end of 
that sequence. The 452 nucleotides of 10-5 had 62.2% identity 
with nucleotides 1341 through 1806 of CYP3A13. In the coding 
sequence, which includes nucleotides 1 through 255 of 10-5, 
there was 77.0% identity with CYP3Al3. An asterisk marks the 
end of CYP3All. 
3Al3 1335 
10-5 
3All 
3Al3 1405 
10-5 
3All 
3Al3 1475 
10-5 
3All 
Table 12 
cDNA Sequence Derived from Phage 10-5. 
GA TC A CA CA G CC G G A 
AGCAAAGAGA ACAAGGGCAG CATTGATCCT TATTTATATA TGCCCTTTGG AATTGGACCC AGGAACTGCA 
G G C GA C 
C A AC G TGTC G CC CA TG 
TTGGCATGAG GTTTGCTTTC ATGACTATGA AACTTGCTCT CACTAAAGTT ATGCAGAACT TTTCCTTCCA 
C A A C 
A TG C T A A C AC C 
GCCTTGTCAG GAAACACAGA TACCTCTGAA ATTAAGCAGA CAAGGACTTC TTCAACCAGA AAAACCCATT 
A 
3Al3 1545 C A TT CA A AGAC G G AT A A AAT GG TG TT AT TAT 
10-5 GTTCTAAAGG TTGAGCCACG GGATGTAGTT ATAACTGCAG CATGAGT ...• CTCCCTCAA GCAGTTGCCC 
3All T C C G . . . . G CTT 
3Al3 1615 CCT GGAC CCA T TCATA TGTG TG ATC G AAAGA G AT AT TC GC CT 
10-5 TGAGTTCTTC AGAAAGGCA ••••• GTGTCT AAGAACATCA GATATGTTAG TTTCATCA .• TGAGTAAAAA 
3All . . • • • G C T 
3Al3 1685 C TGA G T CC TG CT T ACTT GC CA TC TGT AA GTT CTTC GTG GA ATA G 
10-5 TCGAGATGAA TAAGGGGCTT AATAGATTGA CTTTTGATTC ATGGTTAAAG ATTCAGTACA TCACTGCAGA 
3All T * 
3Al3 1761 G G AA GAC ACAAA C A A AATAT C CC TGG 
10-5 CTTTCTCAGT GTCTGTACAG GTTA •.• TCA TCTAATTACC GAATTC 
1.1.0 
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2 oR) that hybridized to the rat CYP3A sequence were used to 
prepare cDNA and a portion of the DNA was digested with EcoRI, 
subjected to electrophoresis, transferred to nitrocellulose by 
southern Blot and hybridized with cDNA prepared from plasmid 
1-3 (Figure 8). Plasmid 1-3 cDNA was used as a probe because 
it contained sequences closest to the 5 1 end of the known 
mouse and rat CYP3A sequences. Plasmids containing inserts 
with two different lengths were isolated from 17R (Figure 9A) 
and purified cDNA was used for dideoxy chain termination 
sequencing as described above. Three consecutive cDNA pieces 
were sequenced (two were the same size) but these did not 
include the 5 1 end of the gene (Figure 9B). 
Since screening the pregnant mouse library did not yield 
a cDNA for the portion of the gene corresponding to the known 
protein sequences, reverse transcription of total RNA prepared 
from a day six gestation mouse and Polymerase Chain Reaction 
amplification were used to obtain further sequences. The 5 1 
primer for PCR amplification of reverse transcribed DNA 
prepared from total RNA corresponded to positions 398 through 
418 of CYP3All. This sequence from plasmid 1-3 was the 
furthest upstream sequence available and is in a region that 
is highly conserved between the two rat CYP3A sequences and 
among the four human CYP3A sequences. The sequence from 
plasmid 1-3 was also identical to the sequence for mouse 
CYP3All nucleotides 398 through 418. The 3 1 primer was the 
reverse of plasmid 17RlO-l, corresponding to positions 1589 
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Figure 8. EcoRI Digests of cDNA Detected by Rat PCN2. 
The pregnant mouse liver library was screened for plaques 
containing cDNA that hybridized with Rat PCN2. Bacteriophage 
from twenty plaques that hybridized to Rat PCN2 were grown in 
a 15 ml culture as described in the methods. Purified phage 
DNA was digested with EcoRI, and the digests were separated by 
1% agarose gel electrophoresis, transferred to nitrocellulose 
by capillary blotting, and hybridized with DNA probes prepared 
from plasmid 1-3. 
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Figure 8. EcoRI Digests of cDNA Detected by Rat PCN2. 
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Figure 9. Map of Mouse Cyp3a Sequences Detected with Rat PCN2 
(CYP3A2) Probe. 9A. EcoRI digests of plasmids derived from 
bacteriophage 17RlO. 9B. The location of plasmid cDNA derived 
from bacteriophage 17Rl0 in relation to CYP3Al1 and CYP3A13 
from male mice. The EcoRI sites, the ATG start site and the 
TGA termination signal are shown as in Figure 7. 
A. 
B. 
ATC 
Ja--11 • 
Ja-1.3 ATC • 
17R10 
e: 
.. 
( 
.. 
.,..--,. 
! j8§i 
(/) 2036 
o 1636 
a::: 
~ 1018 
z 
~ (/) 506 
<: 396 
6 ~~~ 
115 
S 1 2 3 4 5 6 7 8 S 
£ ( TCA 
• .. • ( TCA 
.. .. 
E £ £ TCA e: 
.. .. ... .,,. 
Figure 9. Map of Mouse Cyp3A Sequences Detected with Rat PCN2 
(CYP3A2) Probe. 
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through 1607 of CYP3All and included the TGA stop signal. The 
primers and their positions relative to CYP3All are shown in 
Figure lOa. When these primers were used to amplify first 
strand cDNA prepared from day six gestation mouse liver total 
RNA, a product of approximately 1200 base pairs was obtained. 
This PCR product was ligated into pAMP and used to transform 
Dh5a cells. The plasmid DNA was digested with PstI and 
HindIII restriction enzymes and the products were separated on 
a 1% agarose gel, transferred to Immobilin-s membrane and 
hybridized to biotinylated DNA from plasmid 1-3. As shown in 
Figure lOb, both the 1200 bp insert and the undigested vector 
contained DNA that hybridized with the CYP3A related probe. 
The PCR product was partially sequenced using sequencing 
primers from both sides of the cloning site. The sequence 
from the 3' end was identical to sequences from 17Rl0 derived 
plasmids from each side of the EcoRI site at nucleotides 1521 
through 1526. The sequence from the 5' end of the PCR product 
was 100% identical with the sequence from phage 1 for the 
region corresponding to CYP3All nucleotides 419 through 507. 
The longest series of overlapping sequences was obtained 
from phage 17Rl0. When compared with the other mouse Cyp3a 
sequences there was 95% identity between CYP3All and 17Rl0 and 
69% identity between CYP3Al3 and 17Rl0. When only the coding 
regions of CYP3Al3 and l 7Rl0 were compared the sequence 
identity increased to 80%. The two sequences from pregnant 
mouse liver phage 10 and 17R had 94% identity with each other 
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Figure 10. Polymerase Chain Reaction Amplification of cDNA. 
lOA. Map of the 5' and 3' Primer for Polymerase Chain Reaction 
Amplification of cDNA. The first strand cDNA was prepared by 
Reverse Transcription of total RNA prepared from a day six 
gestation mouse. The uracil residues in the primers CUA 
leader sequences were removed with uracil DNA glycosylase 
before annealing with the GAT repeats at the ligation site of 
the plasmid pAMP 1. 10B. The ligated PCR product was used to 
transform Efficiency DH5a Competent cells. Plasmid DNA was 
purified and digested with Pstl and HindIII, separated on a 1% 
agarose gel and blotted to Immobillin-s, and hybridized with 
biotinylated phage 1 DNA. The insert DNA contains 
approximately 1200bp. 
A. 
ATG E 
3a-11 
CUACUACUActJATTrGGCCCAGTGGGGATAATG 
B: 
0 
9416 
6557 
4361 
2322 
2027 
564 
1 18 
E E lCA 
GTAAGGGAGTTCCTCAAGAUACUACUACUAC 
Figure 10. Polymerase Chain Reaction Amplification of cDNA. 
l0A. Map of the 5' and 3' Primer for Polymerase Chain Reaction 
Amplification of cONA. l0B. The insert 1200 bp cONA hybridized 
to cONA prepared from phage 1. 
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in the coding region. This decreased to 72% when only the J' 
noncoding sequences were compared or 84% for the combined 
coding and noncoding regions. 
Northern Blot Analysis of Total RNA 
There is at least one example of CYP3 mRNAs of different 
length being transcribed from the same gene, that is for the 
rabbit CYP3A6 gene (Dalet et al. 1988). To test for different 
size mRNAs for CYP3As in mouse liver two sets of total RNA 
prepared from livers of male, virgin female, and gestational 
days six, ten and seventeen mice were fractionated using 
formaldehyde denaturation conditions. The gel was cut between 
the two sets of samples and one half of the gel was stained 
with ethidium bromide to visualize the standards and the rRNA. 
The apparent size of the ribosomal RNAs agrees well with the 
expected size of 4718 and 1874 bases (Hassouna et al. 1984, 
Raynal et al. 1984), indicating that the total RNA was not 
degraded (Figure llB). The other set of samples was 
transferred to Immobilin s nylon membrane, hybridized with 
biotinylated DNA prepared from plasmid 1-3 and washed with a 
low stringency wash to allow detection of all closely related 
RNAs. As shown in Figure llA, there was no evidence of mRNAs 
of different size in the mouse liver. A single size RNA, 2.4 
kb, was detected for mice in each hormonal state tested. 
Translation of Nucleotide Sequences 
The nucleotide sequences for l 7Rl0 and 10-5 had open 
reading frames that translate into peptides with strong 
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Figure 11. Northern Blot Analysis of Mouse Liver Total RNA. 
llA. Total RNA prepared from mouse liver was fractionated by 
agarose gel electrophoresis and blotted to Immobilin-s 
Membrane by capillary action. The bound RNA was hybridized 
with biotinylated cDNA prepared from phage 1 and detected by 
light emission associated with the dephosphorylation of 
Lumigen PPD. The RNA was prepared from virgin female, Lane 1; 
male, Lane 2; gestation day 6, Lane J; gestation day 10, Lane 
4; and gestation day 17 mice, Lane 5. Each preparation is 
from a single mouse. llB. RNA standards and the total RNA 
samples used for the Northern blot stained with ethidium 
bromide. The 28S and 18S rRNAs are at 4700 and 1900 
nucleotides which agrees with published values of 4718 and 
1874 respectively (Hassouna et al. 1984, Raynal et al. 1984). 
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Figure 11. Northern Blot Analysis of Mouse Liver Total RNA. 
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homology with each other and with the two reported mouse CYP3A 
proteins. The peptide sequence encoded by 17R10 was aligned 
with comparable regions of CYP3All and 3A13 in Table 15. In 
the 146 residue peptide there were 14 amino acid differences 
between CYP3All and 17R10 for 90% homology. There was only 
68% homology between CYP3A13 and 17Rl0 with 46 residues that 
differ. The open reading frame of 10-5 yielded a peptide of 
84 amino acids with 90% and 68% homology with the carboxyl 
terminal region of CYP3All and 3Al3, respectively (see Table 
16). These 84 amino acids of 10-5 had 87% homology with the 
carboxyl terminal portion of 17R10. The highly conserved 
sequences of the heme binding region were underlined and the 
residues which are conserved in all Cytochrome P450s are 
marked with an asterisk above them in Table 15. 
These sequence differences are large enough to suggest 
that they represent four different proteins. At the same time 
the sequence identities were close enough to place each of 
them in the CYP3A subfamily. 
123 
Table 13. cDNA Sequence Derived from phage 17Rl0. Sequences 
from the pregnant mouse liver library were compared with male 
mouse Cyp3a sequences. All sequences for phage 17R10 and the 
sequences from the Reverse transcription and PCR amplification 
using the 5' primer that was the reverse of 17Rl0 sequence 
1589 through 1609 were compiled to derive this sequence. The 
numbers above each line are the nucleotide sequence location 
in CYP3A13. Differences between 17R10 and CYP3A13 or CYP3All 
are shown above or below the sequence for 17R10, respectively. 
There was 94.5% sequence identity between 17R10 and CYP3All. 
The 599 nucleotides of 17R10 had 68.9% sequence identity with 
CYP3A13. This increased to 79.9% sequence identity for the 
coding region. 
1153 
CYP3Al3 
17R10 
CYP3All 
1223 
CYP3Al3 
17R10 
CYP3All 
1293 
CYP3Al3 
17R10 
CYP3All 
1363 
CYP3Al3 
17R10 
CYP3All 
Table 13 
cDNA Sequences Derived from phage 17R10 
C G G G T A C C GGA G C 
ATATTGTGCT TAATGAAACC CTCAGATTAT ATCCCATTGT TACTAGACTT GAGAGAGTCT GTAAGAAAGA 
G C A 
A GC A TC T A TG A A C T A A 
TGTTGAACTC AATGGTGTGT ATATCCCCAA AGGGTCAATG GTGATGATTC CATCTTATGC TCTTCACCAT 
CA 
GA T G G GCC A T C A 
GACCCACAGC ACTGGCCAGA CCCTGAAGAA TTCCAAGCTG AAAGGTTCAG CAAGGAGAAC AAGGGCAGCA 
T G C 
CA AG C G G A 
TTGATCCTTA CGTATATCTG CCCTTTGGAA TTGGACCCAG GAACTGCATT GGCATGAGGT TTGCTCTCAT 
T G A C 
1433 
CYP3Al3 A C G C TG TC G C C A TG A TG C 
CTTGCTGTCA CTAAAGTTCT GCAGAACTTT TCCTTCCAGC CTTGTCAGGA AACACAGATA 17R10 GAATATGAAA 
CYP3All C A A C A 
Table 13 is continued on page 125. 
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1503 
CYP3Al3 TA 
17Rl0 CCTCTGAAAT 
CYP3All 
1573 
CYP3Al3 AGAC G 
17Rl0 ATGCAGTTAT 
CYP3All C 
1643 
CYP3Al3 ATA TGTG 
l 7Rl0 •. GTGTCTAA 
CYP3All 
1713 
Table 13 Continued 
A C C AC CC T CA A 
TAAGCAGACA AGGAATTCTT CAACCAGAAA AACCCATTGT TCTAAAAGTT GTGCCACGGG 
C G 
G AT A ATAATGG TG TT A T G ATCC T GGAC A CCA TC 
AACTGGAGCA TGA CAT TCCCTCAAGG AGTTCTTCTG AGTTCTTCAG GAAGGCA ••. 
GTC A 
TG ATC G TAAAGA G AT ATT CGTGCA TCC GG TC CGGGTG TCT 
GAACATCAGA CACTTTAGTT TCATCAGAGT AAAATCCAGA TGAATAATGG ACTTAATAGA 
G T TG G G * 
CYP3Al3 AC C CAG CTC G TGA AGTTA T TG GA A AT AGG 
17Rl0 TTGATTTTGA TTCATGGTTA AAGATTCAGT CATCACTGAG CCGAATTC 
CYP3All 
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Table 14. Comparison of Pregnant Mouse cDNA Sequences. The 
cDNA sequences isolated from pregnant mouse liver were 
compared in the coding and the noncoding 3' regions. The 
identity between the two sequences was 95% in the coding 
region, 86% in the noncoding region and 92% for the entire 
sequence. 
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Table 14 
Comparison of Pregnant Mouse cDNA Sequences 
10-5 AGCAAAGAGA ACAAGGGCAG CATTGATCCT TATTTATATA TGCCCTTTGG AATTGGACCC AGGAACTGCA 
17R10 G CG C 
10-5 TTGGCATGAG GTTTGCTTTC ATGACTATGA AACTTGCTCT CACTAAAGTT ATGCAGAACT TTTCCTTCCA 
17R10 C A G C 
10-5 GCCTTGTCAG GAAACACAGA TACCTCTGAA ATTAAGCAGA CAAGGACTTC TTCAACCAGA AAAACCCATT 
17R10 A 
10-5 GTTCTAAAGG TTGAGCCACG GGATGTAGTT ATAACTGCAG CATGAGTCTC CCTCAAGCAG TTGCCCTGAG 
17R10 A T C G CAT G CTTC 
10-5 TTCTTCAGAA AGGCAGTGTC TAAGAACATC AGATATGTTA GTTTCATCAT GAGTAAAAAT CGAGATGAAT 
17R10 G C CT CA 
10-5 AAGGGGCTTA ATAGATTGAC TTTTGATTCA TGGTTAAAGA TTCAGTACAT CACTGCAGAC TTTCTCAGTG 
17R10 T A GCCGA A . . . . . . 
10-5 TCTGTACAGG TTATCATCTA ATTACCGAATTC 
17R10 
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Table 15. Translation of cDNA 17R10. The translation of the 
open reading frame for cDNA 17R10 was compared with the 
carboxyl terminal sequences of CYP3All and CYP3Al3 . The 
underlined sequence is the highly conserved heme binding 
region. The asterisks label the amino acids that are 
conserved in all cytochrome P450s. 
Table 16. Translation of cDNA 10-5 and Comparison with CYP3All 
and CYP3A13. The highly conserved heme binding region is 
underlined and highly conserved amino acids are labeled with 
an asterisk as in Table 15. 
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Table 15 
Translation of cDNA 17Rl0 
3All M AN T 
l 7Rl0 IVLNETLRLY PIVTRLERVC KKDVELNGVY IPKGSMVMIP SYALHHDPQH 
3Al3 M V AG T I LF TV TF K KY 
3All SE P * N * * *L* * L 
l 7Rl0 WPDPEEFQAE RFSKENKGSI DPYVYLPFGI GPRNCIGMRF ALMNMKLAVT 
3Al3 E RP K QD N M S I V LV 
3All 
17Rl0 
3Al3 
3All 
10-5 
3Al3 
3All 
10-5 
3Al3 
IM K L 
KVLQNFSFQP CQETQIPLKL SRQGILQPEK PIVLKVVPRD AVITGA 
R TV K E K L N LLL S ETVSDE 
Table 16 
Translation of cDNA 10-5 
V L * N * * *L* *L 
SKENKGSI DPYLYMPFGI GPRNCIGMRF AFMTMKLALT 
K QD N ML s LI V V 
I K A 
KVMQNFSFQP CQETQIPLKL SRQGLLQPEK PIVLKVEPRD VVITAA 
R L TV K E K N LLL s ETVSDE 
Discussion 
PUrification of cytochrome P450gest 
Cytochrome P450gest can be purified to electrophoretic 
homogeneity by a combination of chromatography steps that are 
similar to the steps required for purifying other cytochrome 
P450s from hepatic microsomes. The final HPLC purification 
step indicates that there are two proteins. Since these 
proteins had separated as a single protein in all the earlier 
steps, it was possible that they had very similar structures. 
The N-terminal amino acid sequence of the purified proteins 
was consistent with similar structures since they differed at 
only one of twenty-seven amino acids. This sequence also 
placed both P450s in the CYP3A subfamily. When purified 
P450gestl and gest2 were reconstituted with lecithin, 
phosphatidylserine and sodium chelate, both enzymes had 
testosterone 6-~ hydroxylase activity, but when the protein 
was reconstituted with dilauroylphosphatidyl choline the 
enzymatic activity was very low. This difference in activity 
when different lipids are used for reconstitution is 
characteristic of the CYP3A subfamily (Imaoka et al. 1988, 
Halvorson et al. 1990). The specific activity for P450gestl 
was very similar to that of rat CYP3A2 but P450gest2 had only 
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about half the testosterone 6~ hydroxylase activity of 
P450gestl or rat CYP3A2. The differences in activity- may 
reflect small differences in the amino acid sequences of the 
two P450gest proteins. This could be similar to the 
differences in mouse CYP2A4 and CYP2A5 where a change in a 
only three amino acids changes the substrate specificity 
towards testosterone or coumarin (Lindberg and Negishi 1989). 
Induction of P450gest 
The HPLC method used to monitor P450gest induction did 
not separate P450gestl and gest2, nor could the rabbit anti 
P450gest antibodies distinguish between the two proteins. 
Therefore induction of cytochrome P450gest will be discussed 
as if it were a single protein. Cytochrome P450gest appears 
to be a unique enzyme that is induced during gestation and 
lactation in the mouse. The protein is not induced by 
treatment with chemicals that are known to induce other P450s. 
These include the CYPlA inducer 3-methylcholanthrene, the CYP2 
inducer phenobarbital, the CYP3A inducer PCN and the 
peroxisome proliferator and CYP4 inducer diethylhexyladipate 
(Lambert et al. 1987, Lietz et al. 1987). The glucocorticoid 
dexamethasone does not induce P450gest as shown in Figure 3. 
In contrast to the ineffectiveness of the exogenous CYP 
inducers, pregnancy and lactation both induce P450gest. The 
protein can be induced by treatment with endogenous hormones 
in a protocol that mimics the hormonal changes that induce 
lactation in the mammary gland. 
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Induction of P450gest differs from induction of lactation 
in certain aspects. Induction of lactation in 
hypophysectomized-ovariectomized-adrenalectomized virgin 
female mice requires both growth hormone and prolactin in the 
presence of hydrocortisone, estradiol and progesterone (Nandi 
1956). The virgin mice in this study were intact and 
therefore the hormone treatments were added to the normal 
circulating levels. The only hormone that had any effect on 
P450gest induction singly was prolactin and the effect was not 
as large as that induced by pregnancy. Both growth hormone 
and hydrocortisone were needed in addition to the normal 
background levels of hormone to induce P450gest to the level 
of pregnancy. This additive effect of glucocorticoid and 
growth hormone is different from the regulation of male rat 
P450s in hepatocyte cultures, where continuous growth hormone 
decreases and dexamethasone increases mRNA for CYP2Cll. 
Growth hormone and dexamethasone each decrease mRNA for male 
rat CYP2Cl3 (Liddle et al. 1992). The requirement for both 
growth hormone and glucocorticoid also differs from the 
induction of the female specific rat CYP2Cl2 that is induced 
by growth hormone treatment of primary rat hepatocytes in a 
hormone free media (Legraverend et al. 1992). It also differs 
from corticosterone 6,8-hydroxylase activity in toad kidney 
epithelial cells in which corticosterone will induce the 
activity in the absence of other hormones (Grogan et al. 
1990). 
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In mammary gland development prolactin and growth hormone 
together induce more cell differentiation than either- one 
alone (Nandi 1958). In contrast prolactin decreases the 
effect of growth hormone and hydrocortisone on the induction 
of P450gest. A similar interaction could be occurring during 
pregnancy and lactation. At eighteen to twenty days gestation 
in C57BL/St mice serum growth hormone levels are double the 
levels present in mice in other hormonal states including 
nonpregnant or lactating female and male mice. Prolactin 
levels are highest in the nonpregnant adult females and 
decrease in the order pregnant > lactating (ten to twelve 
days) >> male (Sinha 1980). Other studies have demonstrated 
higher levels of prolactin during the first eight to ten days 
of gestation with low levels on days twelve to sixteen (Murr 
et al. 1974, Soares and Talamantes 1982) , with a sharp 
increase in prolactin levels just before parturition (Murr et 
al. 1974). These changes are interesting because the levels 
of P450gest are high on gestation days fourteen and sixteen 
when the prolactin level is low, then decrease until a few 
days after parturition during the period when the prolactin 
level is increased. Hepatic P450gest increases again during 
lactation when the prolactin levels are less than in pregnant 
mice. It is possible that growth hormone and glucocorticoid 
induce one of the two P450gest proteins and prolactin induces 
the other. Prolactin could decrease production of the growth 
hormone stimulated protein. 
134 
Numl:>er of CYP3A Proteins in Mice 
The CYP3A subfamily was considered to contain more·than 
one member even before any sequences were obtained because rat 
pP450PCN-10 hybridizes to more than 30 kilobases of mouse 
genomic DNA (Simmons et al. 1985), although this could 
represent a genomic sequence with several introns or with very 
long introns, as has been shown for rat and human CYP3As 
(Miyata et al. 1991; Itoh et al. 1992) . Two nucleotide 
sequences that encode CYP3A proteins have been reported for 
mice. Both of these cDNA sequences, which are 76% identical 
to each other through the coding region, were obtained by 
screening a library prepared from the liver of dexamethasone 
treated male ddY mice (Yanigimoto et al. 1992). Both the N-
terminal amino acid sequences of the purified proteins (Table 
8) and the amino acid sequences deduced from the cDNA sequence 
of 10-5 and 17R10 (Tables 15 and 16) are related to Cyp3All 
and 3A13 . The per cent sequence identities are shown in 
Tables 9 and 17. The per cent identity for the sequence of 
the c-terminal 146 amino acids for any pair of proteins in 
Table 17 is similar to the nucleotide sequences for the same 
pair of full length cDNA sequences in Table 1. Therefore 
comparisons between these regions could give an estimate of 
the sequence identities that will occur when the full length 
amino acid sequence is available. Among the mouse and rat 
CYP3A sequences, CYP3Al3 has the greatest difference from any 
other peptide in Table 17. The nucleotide sequences in Tables 
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12 and 13 demonstrate that nucleotide sequence identity 
decreases after the TGA stop codon especially between CYP·3A13 
and the other cDNA sequences. Therefore CYP3A13 would appear 
to be different than the other murine CYP3As. 
There is no overlap between the sequences from the 
purified protein and the sequences deduced from the cDNA. If 
the sequences from the protein and those deduced from the cDNA 
are for the same gene product, there must be at least four 
CYP3A enzymes in the mouse. If they are for different 
proteins, there would be at least six CYP3A proteins. Whether 
there are four or six CYP3A proteins in the mouse will become 
clear when the complete cDNA sequence is available. The more 
conservative estimate is that there are four hepatic CYP3A 
related proteins in mice. 
The existence of four CYP3A proteins in mice, two 
identified in male ddY mice and the two described in this 
work, would be consistent with the number of CYP3A proteins 
found in at least two other species. Four CYP3A gene products 
for humans have been studied extensively with respect to 
differential expression and substrate specificity. In rats, 
four proteins with testosterone 6p-hydroxylase activity have 
been purified although only three complete cDNA sequences have 
been reported. Three of these proteins have N-terminal amino 
acid sequences that are at least 75% identical with each other 
(Nagata et al. 1990). Two of these three include sequences 
identical to the N-terminal amino acid sequences of CYP3Al and 
3A2. The N-terminal amino 
identical to the deduced 
acid sequence for 
sequence for cDEX 
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P-4506p_ 4 is 
(Kirata· and 
Matsubara 1993) . The fourth protein with testosterone 6~-
hydroxylase activity has an N-terminal sequence that has only 
51% identity with CYP3Al or 3A2 but it has 85% identity with 
hamster CYP3Al0, the lithocholic acid 6~ hydroxylase. 
Although the deduced amino acid sequence is limited to 
the carboxy-terminal end, the sequence in that region provides 
evidence that 17R10 and 10-5 represent new members of the 
mouse CYP3A subfamily. The amino acid sequence comparisons 
between male and pregnant mouse CYP3A proteins in Table 17 
demonstrate that there was 92.4% identity between 17R10 and 
10-5, below the 97% identity expected for allelic variants. 
The pregnant mouse cDNA sequences probably are not allelic 
variants of the male mouse CYP3As. The deduced amino acid 
sequence identity between CYP3All and either 17R10 or 10-5 was 
90%. This identity was less than 70% between CYP3A13 and 10-5 
or 17Rl0. 
Additional information that is consistent with 17R10 and 
10-5 representing different genes than CYP3All or CYP3A13 
exits in the 3' noncoding region of the mouse CYP3As. The 
known CYP3A genes appear to fall into one of three types based 
on a comparison of the 3' end. One type is approximately 100 
bases shorter than the others. Sequences for short CYP3A's 
end approximately 100 base pairs after the termination signal, 
that is, at approximately 1700 base pairs. This type includes 
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Table 17. Amino Acid Sequence Identities for Mouse and Rat 
CYP3As. The 146 N-terminal amino acid sequences that are 
comparable to l 7R were used to determine the identities 
between the previously published sequences. The mouse 
sequences 10-5 and 17R and the rat sequence cDEX do not have 
systematic names. 
10-5 
17R 
3a-ll 
3a-13 
3Al 
3A2 
cDEX 
Table 17. Amino Acid Sequence Identities 
for Mouse and Rat CYP3As. 
10-5 17R 3a-ll 3a-13 3Al 3A2 
100 
92.4 100 
90.4 90.4 100 
64.3 69.2 71.2 100 
83.7 87.0 89.0 75.3 100 
81.3 84.9 85.6 70.8 84.9 100 
83.3 86.3 87.0 77.4 100 84.9 
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cDEX 
100 
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human CYP3A5, mouse CYP3All and the 1706 base pair rabbit 
CYP3A6. Both 17Rl0 and 10-5 were longer than 3A11 after. the 
stop codon. The other two types of CYP mRNA are up to 300 
base pairs longer after the termination signal but differ in 
that the second type has a ten to twenty base pair insert as 
compared to the third type. This insert occurs approximately 
100 base pairs after the termination signal, and after the end 
of the sequences for the three short CYP3As. An insert is 
identified only if, in addition to the presence of extra 
nucleotides in one sequence, there is recognizable nucleotide 
sequence identity further downstream. 
The differences in the length of RNA after the coding 
region may affect differences in expression of the gene or 
support different regulation of the same gene. An example of 
a short mRNA that is expressed differentially is CYP3A5, a 
protein that is expressed in only a fraction of human livers 
with detectable levels in a larger proportion of livers from 
children and adolescents as compared to adults (Wrighton et 
al. 1990). 
Expression of different lengths of the same gene also 
occurs. In rabbit, there are two mRNA species for CYP3A6 that 
differ only in length. The 1768 base mRNA has a Poly(A) tract 
23 bases after the AATAAA polyadenylation signal. There is 
another polyadenylation signal approximately 100 bases 
downstream that is followed by a polyadenylation site that 
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Table 18. Classes of CYP3A mRNA. Messenger RNAs in the short 
group end about 100 nucleotides after the stop codon. The 
long with insert group contain a fifteen to twenty base insert 
as compared to the long group. The insert occurs ten to 
twenty bases after the end of the sequences for the short 
group. 
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Table 18. Classes of CYP3A mRNA. 
mRNA class 
Short Long Long with insert 
3AS 3Al 3A2 
3A6(short) 3A3 3A4 
3All 3A13 3A6 (long) 
3A7 
3A8 
3A10 
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starts at base 1881 (Potenza et al. 1989). These two mRNAs 
are expressed differently in the developing rabbit, with. the 
1768 base species appearing one day before the longer species 
in fetal rabbit liver. The 1768 base RNA is present at 
higher levels than the 1880 base RNA in hepatic RNA prepared 
from one, two or three week old rabbits, but the levels of the 
two RNAs are equivalent in adult rabbits (Pineau et al. 1991). 
Two human CYP3A4 cDNA clones that differ in length also differ 
in level of expression. The clones NFlO and NF25 differ by an 
extra 814 bases at the 3' end of NFlO. The only other 
differences between these two clones are a three base deletion 
in the cloning region and a one base insertion in the 3' 
noncoding region in the NFlO clone as compared to the NF25 
clone. When mRNA was prepared from a series of human livers 
and probed with oligonucleotides specific for each, the 
expression of NF25 was ten fold higher in eleven of twelve 
samples. The remaining human liver expressed only NFlO (Bork 
et al. 1989). 
These differences in expression could be related to mRNA 
stability that is regulated by sequences in the 3' 
untranslated region. There are at least two types of elements 
in the 3 1 untranslated region of a gene in addition to the 
poly(A) tail that affect mRNA stability (Sachs 1993). 
Regulation of mRNA stability for phosphoenolpyruvate depends 
on a glucocorticoid-responsive sequence downstream of the stop 
codon (Petersen et al. 1989) and regulation of transferrin 
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mRNA turnover depends on iron responsive elements as well as 
another sequence in the 3' region (Casey et al. 1989). 
The Northern blot analysis of total hepatic RNA prepared 
from pregnant and virgin female mice and from male mice did 
not indicate more than one length for RNA hybridizing to the 
CYP3A probe (Figure 12). Two RNA bands could have occurred in 
the male mouse for which the two published sequences differ by 
346 bases. Since CYP3All and CYP3Al3 were isolated from 
dexamethasone treated mice, it may be that the short CYP3All 
mRNA is not expressed in untreated male mice. 
The insert in the long mRNA sequences can be associated 
with differential expression of closely related genes. CYP3A4 
clone NF25 and CYP3A3 clone HLp represent two genes with over 
98% nucleotide sequence identity that encode proteins with 
only eight amino acid differences. In addition, there is a 19 
base pair insertion in the 3' noncoding region of NF25 
relative to position 1703 of HLp (shown as CYP3A4 insert into 
CYP3A3 in Table 18). The presence of this insert was the 
basis for assigning them different subfamily numbers. 
Hybridization of mRNA from the same human livers as described 
above demonstrated an eight fold increase in NF25 (CYP3A4) 
mRNA over the level for HLp, a CYP3A3 (Bork et al. 1989). An 
additional human protein, designated CYP3A7, is the major 
cytochrome P450 in human fetal liver but is expressed at a low 
level in adult livers. The cDNA encoding this protein has 92% 
sequence identity with CYP3A3, but there is a 20 base pair 
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insertion in CYP3A7 at nucleotide 1696 of CYP3A3 (Komori et 
al. 1989). 
The only hamster CYP3A that has been sequenced includes 
an insert as compared to rat CYP3Al (shown in Table 18 as 
CYP3Al0 insert into CYP3Al). Gene regulation of CYP3Al0 has 
many similarities with the regulation of rat CYP3A2 which also 
has an insert as compared to CYP3Al (Table 18). Constitutive 
and cholic acid induced expression of CYP3Al0 in the hamster 
is gender and age specific. Untreated female hamsters have a 
50-fold lower level of CYP3Al0 mRNA than males and the level 
is not induced by dietary cholic acid. In males, cholic acid 
induces the level of CYP3Al0 in young (four to eight week old) 
but not in older males (Teixera and Gil 1991). 
The same CYP3As that had inserts with respect to CYP3Al 
also have inserts with respect to CYP3A3, with one difference. 
The GCG GAP program identifies two CYP3A6 inserts with respect 
to CYP3Al but there is a single longer insert with respect to 
CYP3A3. CYP3Al3 does not fit the pattern, since the insertion 
sites and the length of the insert for CYP3Al3 are not as 
consistent as in CYP3Al (Table 19). When 10-5 and CYP3A13 
are compared using the GAP program from GCG, there are three 
inserts, but CYP3Al3 has the extra nucleotides with respect to 
10-5. Each of these inserts is only five nucleotides or less, 
and there is very little sequence identity after the stop 
codon between CYP3Al3 and the other mouse CYP3A sequences. 
These differences in sequence may be too large to make an 
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Table 18. Insertion Sequences into CYP3A1 and CYP3A3. 
Sequences at the insertion site of CYP3A1 or CYP3A3 are in 
upper case letters. The insertion sequences are in lower case 
letters. The nucleotide sequences were compared using the GCG 
program Best. Potential polyadenylation signals are 
underlined. 
Table 18. Insertion Sequences into CYP3Al and CYP3A3. 
CYP with 
insert 
3A2 
3A4 
3A6 
3A6 
3A7 
3A8 
3Al0 
10-5 
3A2 
3A4 
3A6 
3A7 
3A8 
3Al0 
Insertion Site 
in CYP3Al 
1714 
1713 
1661 
1756 
1713 
1713 
1714 
1716 
Sequence with Insert 
GTTTgatgcatggttaaTGA 
TGTTgcataaataaccgTTGA 
CTTTtactttgtgAATT 
ATGTgctgACCC 
TGTTgcataaataaccgTTGA 
TGTTgcataaataaccaTTGA 
GTTTgatgattgaTGA 
TTTTgattcatggttaaaGATT 
Insertion Site 
in CYP3A3 
1697 
1703 
1696 
1696 
1696 
1684 
ATAGttaaagatttggtacaTATC 
ACCGgggattctgtacatgcattGAGC 
CATAgagtgatggtggagtgtGTAT 
CATAaataatcagggattctgtacGTAT 
CATAaataaccagggattctgtacGTAT 
TCCAtgattATGA 
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Table 19. Insertion Sequences into CYP3Al3 and 10-5. 
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Table 19. Insertion Sequences into CYP3Al3 and 10-5. 
CYP with Insertion Site Sequence with Insert 
insert in 3A13 
3Al 1587 AGTGgatcatgattttccATGA 
3A2 1587 AGTGgagcctgactttccctcaATGA 
3A5 1600 TAATtctaaggaGGTC 
3A6 1597 GAATttcctatggaattttgcAATG 
3A7 1597 GAATtccctaaggaAATG 
3A8 1603 TGGTaaggacttctgCTGT 
3Al0 1623 TCCTtcaatgggactgtgtcGTGG 
3A2 1680 ATAAattgactgcTTTC 
3A4 1696 TGAAataaccggGGAT 
3A6 1701 GATTggtggaCCGG 
3A7 1692 CTCCataaataaTGAA 
3A8 1696 TGAAataaccagGGAT 
3Al0 1695 GAATttCCAG 
Insertion Site 
in 10-5 
3Al3 1600 GAGTaatgGTCT 
3Al3 1639 GGCAttcatGTGT 
3Al3 1678 ATCAatTGAG 
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insert significant. This is consistent with CYP3Al3 being a 
different enzyme as compared to the other mouse sequences~ As 
shown in Table 18, the pregnant mouse sequence 10-5 has an 
insert with respect to CYP3Al making it a different type with 
respect to the 3' end than either Cyp3Al3, a long sequence, or 
Cyp3All, a short sequence. There is not sufficient sequence 
identity between 10-5 and CYP3A3 at the 3' end to make a 
potential insert apparent. The sequence 17Rl0 does not fit 
into one of these types al though the sequenced length is 
greater than for the short type. The sequence of the insert 
in 10-5 also occurs in 17Rl0 but comparing 17R10 and CYP3Al 
does not indicate an insert possibly because the remaining 
sequence between the "insert" and the EcoRI site at the end of 
17Rl0 have very little identity with the corresponding 
sequences in CYP3Al. Whether 17Rl0 and 10-5 belong in the 
same or different types might become clear if sequences beyond 
the EcoRI site were obtained. 
Physiological Function of CYP3A Proteins 
The rapid induction of P450gest during gestation and 
lactation would be consistent with a specific function for a 
metabolic product of the enzyme. The physiological substrate 
for P450gest is not known. Testosterone was the only steroid 
that was tested as a substrate for purified P450gest but other 
steroids such as progesterone or estradiol are substrates for 
some of the testosterone metabolizing P450s including human 
CYP3A4 (Waxman et al. 1988) and rat CYP2Cl3 (Swinney et al. 
1987) . 
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One indication that P450gest could have a specific 
function in maintaining pregnancy or in development of the 
fetus is that diethylhexyladipate, a known teratogen, 
decreases P450gest in the HPLC profile of treated pregnant 
animals (Lietz et al. 1987). 
The formation of specific metabolites of testosterone or 
some other steroid in the liver could be simply a degradation 
or detoxification mechanism as has been proposed (Nebert 
1991) . However, the highly specific location for the hydroxyl 
group, the tissue specific expression and the different 
regulatory mechanisms for each P450 suggest that at least some 
of the metabolites could have a specific function (Waxman et 
al. 1983) . An example of a metabolite with a specific 
function is corticosterone 6~-hydroxide which regulates Na• 
transport in A6 epithelia, a toad kidney cell line (Duncan et 
al. 1988). Corticosterone 6~-hydroxylase activity is induced 
in these cells by corticosterone as well as by Cyp3A inducers 
such as TAO and PCN (Grogan et al. 1990). 
An alternate mechanism whereby CYP3A enzymes could help 
maintain the pregnancy could involve the metabolism of 
exogenous substrates. Changes in CYP3A enzymes during 
pregnancy could alter the toxicity of specific substances by 
increasing the amount of a toxic metabolite or decreasing the 
amount of a protective metabolite analogous to the effects of 
induction of CYPlA enzymes (Nebert 1991) . For example 
phenytoin is a substrate for the CYP3A enzymes and is a known 
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teratogen in humans. The induced CYP3A activity could either 
protect the fetus by eliminating the drug rapidly or could be 
detrimental by increasing the concentration of a harmful 
metabolite. 
PUture studies of P450gest 
The complete cDNA sequence and the deduced amino acid 
sequences for the proteins represented by 17R and 10-5 are 
needed. These can be obtained by continuing to use primers 
designed from the available sequences and the Polymerase Chain 
Reaction to isolate and sequence cDNA related to these DNA 
fragments. The RACE (rapid amplification of cDNA ends) system 
should be used to obtain additional sequences at the 3' end. 
Cytochrome P450gest is unique in that it is induced very 
rapidly in adult animals at a well defined time. This should 
make it valuable for studying endogenous induction of a 
protein regulated by hormonal changes. The combination of 
growth hormone and hydrocortisone that was needed for in vivo 
induction differs from the requirements for induction of other 
gender specific cytochrome P450s. The apparent interference 
of prolactin on P450gest induction by growth hormone and 
hydrocortisone suggestes that there could be different 
response elements for prolactin and for growth hormone in the 
upstream region of the P450gest gene. If these response 
factors were overlapping or very close together, binding of 
prolactin to its response factor could block binding of a the 
protein to the growth hormone, hydrocortisone repsonse element 
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expression of P450gest. It is possible that prolactin and 
growth hormone with hydrocortisol induce expression- of 
different proteins since there are two P450gest's that have 
the same HPLC elution characteristics with respect to the 
anion exchange column that was used to monitor hormone 
dependent induction of P450gest. Oligonucleotides designed 
from the J' ends of 17R10 and 10-5 could be used to probe 
total RNA prepared from the livers of nonpregnant and pregnant 
animals to test for differences in expression of these two 
closely related gene products. In addition, these probes 
could be used to test for expression of P450gest in the 
developing mouse embryo and fetus using in situ hybridization. 
If these proteins have a direct role in development they could 
be expressed at specific stages of development or in specific 
organs or tissues. 
The physiological function of Cytochrome P450gest and of 
its metabolic products should be studied. The only potential 
endogenous substrate that has been tested is testosterone. 
Cytochrome P450gest could be expressed in Agtll and 
reconstituted with NADPH dependent P450 reductase in the 
presence of lecithin, phosphatidyl serine and sodium chelate. 
With this system the capacity of P450gest to metabolize other 
steroids such as progesterone or estradiol could be tested. 
Both of these are substrates for other CYP3As in other species 
(Waxman et al. 1988, Namkung et al. 1988). 
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